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ABSTRACT 
 
I. Human Herpesvirus 8 Upregulates Activator Transcription Factor 4 
BACKGROUND: Human herpesvirus 8 (HHV-8) is the primary etiologic agent of 
Kaposi’s sarcoma, a highly vascularised neoplasm of endothelial origin characterized by 
inflammation, neoangiogenesis, and by the presence of characteristic spindle cells. HHV-8 
angiogenic activity is due to the activation of NF-kB and the subsequent induction of 
MCP-1 synthesis. MCP-1 is a chemokine produced by macrophages and endothelial cells 
in response to different stimuli, and is a direct mediator of angiogenesis. HHV-8-induced 
angiogenesis is MCP-1 dependent. However, HHV-8 activation of MCP-1 is not 
completely dependent on NF-kB induction and another cellular factor is involved. A 
potential candidate is the cellular activating transcription factor 4 (ATF4), a stress 
responsive gene. ATF4 is upregulated in several condition, including ER-stress, viral 
infection (e.g. CMV) and in tumours. 
AIM: The aim of the research is to study the interaction between HHV-8 and ATF4, and 
verify whether ATF4 is involved in angiogenesis characteristic of HHV-8 infection. 
METHODS: To demonstrate the effect of HHV-8 on ATF4 expression, Jurkat cells were 
infected with a cell-free viral inoculum, obtained in our laboratory by stimulating 
reactivation of latent HHV-8 in chronically infected cells (PEL-derived). HHV-8 
reactivation from latency was assessed by transfection of BC-3 and BCBL-1 cells (PEL-
derived) with pCG-ATF4 recombinant plasmid. DNA or RNA were analysed by PCR, 
rtPCR or quantitative real time PCR. Promoters activation was assessed by luciferase 
assays. 
RESULTS: HHV-8 upregulates the expression of ATF4 gene, and overexpression of ATF4 
is able to increase replication and transcription of HHV-8, but not to reactivate HHV-8 
from latency. Preliminary results show that ATF4 activates the MCP-1 promoter in 
absence of the NF-kB binding sites. 
CONCLUSION: HHV-8 induces ATF4 expression during the productive infection, 
probably to obtain advantage for its replication and neoplastic development. ATF4 might  
be implicated in HHV-8 induced tumorigenesis, being involved in several aspects of viral 
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replication, and could represent a potential therapeutic target for HHV-8 induced 
transformation. 
 
II. Real Time PCR To Assess Total Bacterial Load in Chronic Wounds 
BACKGROUND: Wounds and wound healing are important issues in chronic patients (i.e. 
diabetes, pressure). Critical colonization and infection are strictly linked to a delay in 
wound healing. Analysis of pathogens present in chronic wound is an essential aspect for 
the wound care. Classic microbiologic methods have several limits to ensure the correct 
analysis of ulcer environment. 
AIM: To analyse total bacterial load by a single quantitative real time PCR reaction in 
swabs and biopsies obtained from infected chronic wounds treated with an innovative 
hydrophobic dressing. 
METHODS: Biopsies were collected at the beginning and after 4 weeks of treatment, and 
swabs were collected once a week for 4 weeks. Real time PCR was carried out on DNA 
extracted from biopsies and swabs amplifying a region of the 16s rRNA gene, highly 
conserved among bacteria. Moreover, DNA extracted from biopsies was also analysed for 
the detection of 2 anaerobic bacteria (B. Fragilis, F. necrophorum, frequently associated 
with delayed healing) by real time PCR amplifying specific unique regions of their 
genome. In parallel, classical culturing methods were performed on biopsies searching for 
Staphylococcus and Pseudomonas species. 
RESULTS: We evaluated the correlation between the molecular data obtained by real time 
PCR and the clinical data, in particular considering the area of the wound. We observed a 
mean 253-fold decrease of the total bacterial load in 10/20 wounds those also showed an 
average 58% decrease of their area. This 10 wounds showed a positive correlation between 
clinical and molecular data. In 5/20 wound, we found a non significant 5,2-fold decrease of 
the total bacterial load, correlate with a 27% increase of the wound’s area. Thus, 75% of 
molecular results (15/20 wounds) were correlate to the clinical data. In contrast, classical 
culturing method did not correlate with the clinical data, confirming that classical methods 
have several limits and disadvantages. B. Fragilis was present in 10/20 wounds, and F. 
necrophorum in 2/20 wounds.  
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CONCLUSION: The molecular approach can be considered a reliable and rapid test to 
assess infection levels in chronic wounds, being more sensitive than the classic cultural 
techniques. The research of specific pathogens is not sufficient to assess the outcome of the 
wounds, whereas total bacterial load can give a prognostic value to the wound care. 
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RIASSUNTO 
 
I. L’herpesvirus umano 8 (HHV-8) “upregola” il fattore d’attivazione trascrizionale 
ATF4. 
INTRODUZIONE: HHV-8 è l’agente eziologico del Sarcoma di Kaposi, un tumore 
altamente vascolarizzato di origine endoteliale caratterizzato da infiammazione, 
neoangiogenesi, e dalla presenza di cellule dalla caratteristica forma spindle. L’attività 
angiogenica di HHV-8 è dovuta all’attivazione del fattore NF-kB e dalla conseguente  
induzione della sintesi di MCP-1, una chemochina prodotta da macrofagi e cellule 
endoteliali in risposta a diversi stimoli. MCP-1 è un mediatore diretto dell’angiogenesi. 
L’angiogenesi indotta da HHV-8 è MCP-1-dipendente, ed è in parte dovuta all’attivazione 
di NF-kB. Dato che l’attivazione di MCP-1 da parte di HHV-8 non è completamente 
dipendente da NF-kB, si è ipotizzato che fosse coinvolto un altro fattore cellulare. Un 
potenziale candidato è ATF4, un fattore cellulare di attivazione trascrizionale, ubiquitario, 
sovraespresso nei tumori e normalmente attivato in risposta a diversi stimoli di stress 
cellulare, come ad esempio lo stress del reticolo endoplasmatico, l’infezione virale. 
SCOPO: Lo scopo della ricerca è stato quello di studiare le interazioni tra HHV-8 e ATF4, 
e di verificare se ATF4 fosse coinvolto nell’angiogenesi indotta da HHV-8. 
METODI: Per dimostrare l’effetto di HHV-8 sull’espressione di ATF4, cellule Jurkat sono 
state infettate con un inoculo virale cell-free prodotto nel nostro laboratorio tramite la 
riattivazione di HHV-8 in cellule latentemente infettate dal virus (derivate da PEL). Per 
verificare l’azione di ATF4 sull’infezione virale, cellule derivate da PEL, BC-3 e BCBL-1, 
sono state transfettate con il plasmide ricombinante pCG-ATF4. I DNA e gli RNA estratti 
sono stati analizzati tramite la PCR, la rtPCR o la real time PCR quantitativa. Per 
analizzare l’attivazione su promotori genici è stato utilizzato il saggio della Luciferasi. 
RISULTATI: HHV-8 “upregola” l’espressione di ATF4, e la sovraespressione di ATF4 è 
in grado di aumentare la replicazione e la trascrizione di HHV-8. Nonostante ciò, ATF4 
non è in grado di riattivare il virus dalla latenza, dal momento che non attiva i principali 
promotori di HHV-8. ATF4 è però in grado di attivare il promotore di MCP-1 in assenza 
dei siti di legame per NF-kB. 
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CONCLUSIONE: HHV-8 induce l’espressione di ATF4 durante l’infezione produttiva, 
probabilmente per trarne vantaggio per la replicazione e per lo sviluppo neoplastico. ATF4 
potrebbe quindi essere coinvolto nella tumorigenesi indotta da HHV-8, essendo implicato 
in diversi aspetti della replicazione virale, e potrebbe rappresentare un potenziale target 
terapeutico contro la trasformazione indotta da HHV-8. 
 
II. Utilizzo della tecnica della real time PCR per quantificare la carica batterica totale 
in ulcere croniche. 
INTRODUZIONE: Le ulcere croniche più comuni includono le ulcere venose, diabetiche e 
da pressione. La condizione cronica indica la mancanza di guarigione per mesi o 
addirittura anni, gravando pesantemente a livello fisico e psicologico sul paziente. La 
colonizzazione e l’infezione di ferite croniche sono strettamente correlate alla mancata 
guarigione. L’analisi dei patogeni presenti è un aspetto fondamentale per il trattamento 
delle ulcere croniche. I metodi della microbiologia classica presentano diversi limiti per 
una corretta analisi del microambiente di un’ulcera, tra cui il maggior tempo impiegato per 
effettuare l’analisi, la minor sensibilità dei risultati, ma soprattutto l’impossibilità di 
coltivare tutti i patogeni presenti in una lesione. Per questi motivi, recentemente sono stati 
considerati con crescente interesse approcci molecolari per quantificare ed identificare i 
patogeni presenti nelle lesioni croniche. 
SCOPO: Lo scopo della ricerca è stato quello di analizzare la carica batterica totale 
attraverso un’unica reazione di real time PCR in tamponi e biopsie di ulcere croniche 
infette trattate con una medicazione idrofobica innovativa. 
METODI: Le biopsie sono state effettuate all’inizio e al termine di 4 settimane di 
trattamento e i tamponi una volta alla settimana per 4 settimane. Il DNA estratto da tali 
campioni è stato processato attraverso la real time PCR amplificando una regione del gene 
codificante per 16S rRNA, altamente conservato in tutti i batteri. Inoltre, il DNA estratto 
dalle biopsie è stato analizzato per la ricerca di 2 batteri anaerobi frequentemente associati 
alla mancanza di guarigione delle ulcere, B. fragilis e F. necrophorum. Parallelamente, le 
biopsie sono state analizzate tramite la microbiologia classica per verificare la presenza di 
Staphylococcus e Pseudomonas spp.  
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RISULTATI: Abbiamo valutato la correlazione tra i dati molecolari ottenuti mediante real 
time PCR e i risultati clinici riguardanti l’area dell’ulcera. E’ stata osservata una 
diminuzione di 253 volte della carica batterica in 10 ulcere su 20, le quali hanno mostrato 
anche una diminuzione media dell’area ulcerosa del 58%. In 5 ulcere su 20, non è stata 
osservata variazione tra la carica batterica all’inizio e al termine del trattamento, e anche il 
risultato clinico è stato negativo, con un aumento medio dell’area dell’ulcera del 27%. 
Quindi, il 75% dei risultati molecolari era correlato con i risultati clinici, mentre i dati 
ottenuti con la microbiologia classica non concordavano con l’andamento delle lesioni, 
confermando che i metodi culturali presentano diversi limiti e svantaggi. Per quanto 
riguarda gli anaerobi, il B. fragilis era presente in 10 ulcere su 20, ed il F. necrophorum in 
2 su 20. 
CONCLUSIONI: La tecnica molecolare può essere considerata un test più rapido, sensibile 
ed affidabile dei metodi microbiologici classici, per valutare i livelli d’infezione in ferite 
croniche e l’efficacia di trattamenti terapeutici. La ricerca di specifici patogeni all’interno 
di una lesione cutanea non è sufficiente per monitorare l’andamento delle ulcere, mentre 
sembra essere molto più rilevante la carca batterica totale, che può dare un valore 
prognostico all’esito della malattia. 
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INTRODUCTION 
 
 
1. Herpesviruses: general features 
 
1.1. Classification of herpesviruses 
More than 100 herpesviruses have been discovered, all of them are double-stranded 
DNA viruses that can establish latent infections in their respective hosts. Eight 
herpesviruses infect humans. The Herpesvirinae family is subdivided into three 
subfamilies: the Alpha-, Beta-, or Gammaherpesvirinae
1
.  
The Alphaherpesvirinae are defined by variable cellular host range, shorter viral 
reproductive cycle, rapid growth in culture, high cytotoxic effects, and the ability to 
establish latency in sensory ganglia. Human alpha-herpesviruses are herpes simplex 
viruses 1 and 2 (HSV-1 and HSV-2) and varicella zoster virus (VZV), and are officially 
designated human herpesviruses 1, 2, and 3. 
The Betaherpesvirinae have a more restricted host range with a longer reproductive 
viral cycle and slower growth in culture. Infected cells show cytomegalia (enlargement 
of the infected cells). Latency is established in secretory glands, lymphoreticular cells, 
and in different tissues, such as the kidneys and others. In humans, these are human 
cytomegalovirus (HCMV or herpesvirus 5) and roseoloviruses (causing the disease 
roseola infantum in children) including human herpesviruses 6A and 6B (HHV-6A and 
-6B) and human herpesvirus 7 (HHV-7). 
The Gammaherpesvirinae in vitro replication occurs in lymphoblastoid cells, but lytic 
infections may occur in epithelial and fibroblasts for some viral species in this 
subfamily. Gammaherpesviruses are specific for either B or T cells with latent virus 
found in lymphoid tissues. Only two human gammaherpesviruses are known, human 
herpesvirus 4, or Epstein-Barr virus (EBV), and human herpesvirus 8, referred to as 
HHV-8 or Kaposi's sarcoma-associated herpesvirus (KSHV). The gammaherpesviruses 
subfamily contains two genera that include both the gamma-1 or Lymphocryptovirus 
(LCV) and the gamma-2 or Rhadinovirus (RDV) virus genera. EBV is the only 
Lymphocryptovirus and HHV-8 is the only Rhadinovirus discovered in humans. LCV 
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are found only in primates but RDV can be found in both primates and subprimate 
mammals. RDV DNAs are more diverse across species and are found in a broader range 
of mammalian species. 
HHV-8 has sequence homology and genetic structure similar to another RDV, 
Herpesvirus saimiri (HVS). The T-lymphotropic Herpesvirus saimiri establishes 
specific replicative and persistent infection in different primate host species, causes 
fulminant T-cell lymphoma in its primate host and can immortalize infected T-cells. 
 
 
 
 Figure 1: Phylogenetic tree of herpesviridae. 
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Human herpesvirus 
type 
Sub 
Family 
Target cell type Latency sites Pathologies 
Herpes simplex-1 
(HSV-1) 
Alpha Mucoepithelial cells Neuron 
Oral and genital 
herpes 
(predominantly 
orofacial) 
Herpes simplex-2 
(HSV-2) 
Alpha Mucoepithelial cells Neuron 
Oral and genital 
herpes 
(predominantly 
genital) 
Varicella Zoster virus 
(VSV) 
Alpha Mucoepithelial cells Neuron chickenpox 
Epstein-Barr Virus 
(EBV) 
Gamma 
B lymphocyte, 
epithelial cells 
B lymphocytes 
Infectious 
mononucleosis, 
Burkitt’s lymphoma 
Cytomegalovirus 
(CMV) 
Beta 
Epithelial cells, 
monocytes, 
lymphocytes 
Monocytes, 
lymphocytes  
Mononucleosis-like 
syndrome 
Human herpes virus-6 
(HHV-6) 
Beta 
T lymphocytes and 
others 
T lymphocytes  Roseola infantum 
Human herpes virus-7 
(HHV-7) 
Beta 
T lymphocytes and 
others 
T lymphocytes        Roseola infantum 
Human herpes virus-8 
(HHV-8) 
 Kaposi's sarcoma- 
associated herpes 
virus (KSHV) 
Gamma 
Endothelial cells 
B lymphocytes 
monocytes 
B lymphocytes and  
endothelial cells 
Kaposi’s sarcoma,  
Multicentric 
Castleman disease, 
Primary effusion 
lymphoma 
 
Table 1: Human herpesviruses classification and characteristics. 
 
 
1.2.  Structure of herpesviruses 
Herpesviruses have a central toroidal-shaped viral core containing a linear double 
stranded DNA. This DNA is embedded in a proteinaceous spindle
2
. The capsid is 
icosadeltahedral (16 surfaces) with 2-fold symmetry and a diameter of 100-120 nm that 
is partially dependent upon the thickness of the tegument. The capsid has 162 
capsomeres.  
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The herpesvirus tegument, an amorphorous proteinaceous material that under EM lacks 
distinctive features, is found between the capsid and the envelope; it can have 
asymmetric distribution. Thickness of the tegument is variable depending on the 
location in the cell and varies among different herpesviruses
3
. 
The herpesvirus envelope contains viral glycoprotein protrusions on the surface of the 
virus. As shown by EM there is a lipid trilaminar structure derived from the cellular 
membranes. Glycoproteins protrude from the envelope and are more numerous and 
shorter than those found on other viruses.  
 
                                      
 
Figure 2: Representation of a herpesvirus virion. 
 
 
1.3.  Herpesviruses genome 
Herpesvirus genome studied to date ranges in size from 130 to 235 kbp. 
Herpesvirus DNA is characterized by two unique components, unique long (UL) and 
unique small (US) regions, each flanked by identical inverted repeat sequences. 
Herpesvirus genome also contains multiple repeated sequences 
All known herpesviruses have capsid packaging signals at their termini
4
. The majority 
of herpes genes contain upstream promoter and regulatory sequences, an initiation site 
followed by a 5' nontranslated leader sequence, the open reading frame (ORF) itself, 
some 3' nontranslated sequences, and finally, a polyadenylation signal. Gene overlaps 
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are common, whereby the promoter sequences of antisense strand (3') genes are located 
in the coding region of sense strand (5') genes; ORFs can be antisense to one another.  
 
 
 
Figure 3: Genomic organization of some herpesviruses. HSV, VZV and CMV have inverted repeated 
sequences. 
 
 
Proteins can be embedded within larger coding sequences and yet have different 
functions. Most genes are not spliced and therefore are without introns and sequences 
for noncoding RNAs are present. 
Herpesviruses code for genes that synthetize proteins involved in establishment of 
latency, production of DNA, and structural proteins for viral replication, nucleic acid 
packaging, viral entry, capsid envelopment, for blocking or modifying host immune 
defences, and for transition from latency to lytic growth. Although all herpesviruses 
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establish latency, some (e.g., HSV) do not necessarily require latent protein expression 
to remain latent, unlike others (e.g., EBV and HHV-8).  
 
 
1.4. Replication of herpesviruses 
Herpesviruses can establish lytic or latent infection. 
The lytic stage is divided in 6 phases: 
1. Binding to the cell surface. As many other viruses, cell tropism is determined by 
the availability of the correct receptor on the surface of the cell  
2. Envelope fusion with the plasma membrane 
3. Uncoating. Degradation of the tegument. Capsid is carried to the nuclear 
membrane.  
4. Transcription. The DNA genome then enters the nucleus. This is a very complex 
process, as expected considering the large size of viral genome. Viral DNA replicates 
by circularization followed by production of concatemers and cleavage of unit-length 
genome during packaging. The herpesvirus lytic replicative phase can be divided into 
four stages: 
 α or immediate early (IE), requiring no prior viral protein synthesis. The genes 
expressed in this stage are involved in transactivating transcription from other 
viral genes. 
 β or early genes (E), whose expression is independent of viral DNA synthesis. 
 Following the E phase, γ1 or partial late genes are expressed in concert with the 
beginning of viral DNA synthesis. 
 γ2 or late genes (L), where protein expression is totally dependent upon 
synthesis of viral DNA and expression of structural genes encoding for capsid 
proteins and envelope glycoproteins occurs. 
Herpesvirus DNA is transcribed to RNA by cellular RNA polymerase I. The neo-
formed viral mRNAs block cellular protein synthesis and activate the replication of viral 
DNA. Herpesviruses encode their own DNA-dependent DNA polymerase and other 
enzymes and proteins necessary to replication, such as ori-Lyt (replication start for the 
lytic phase), major DNA binding protein (MDBP) and origin DNA binding protein 
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(OBP). Herpesviruses can alter their environment by affecting host cell protein 
synthesis and host cell DNA replication, immortalizing the host cell, and altering the 
host's immune responses (e.g., blocking apoptosis, cell surface MHC I expression, 
modulation of the interferon pathway).  
 
Figure 4: Representation of lytic phase of herpesviruses. 
 
 
5. Assembly: capsids are assembled in the nucleus. 
6. The viral particles bud through the inner lamella of the nuclear membrane which 
has been modified by the insertion of viral glycoproteins and leave the cell via the 
exocytosis pathway.  
 
In the latent phase, the virus genome depends on the host replication machinery and 
replicates as closed circular episome. Latency typically involves the expression of only 
a few latency specific genes. Generally, most infected host cells harbour latent virus, as 
in the case of HHV-8: when KS tissue or HHV-8 infected cultured cells are analyzed, 
the virus is latent in majority of infected cells. Different signals such as inflammation 
and immunosuppression may cause the virus to enter into a new lytic phase. 
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Figure 5: Herpesviruses replication cycle. 
 
 
2. Human herpesvirus 8 
 
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma associated herpesvirus 
(KSHV), is a member of the Rhadinovirus genus in the gamma-herpesvirus subfamily, 
first detected in 1994 in a patient affected by Kaposi sarcoma (KS)
5
, a neoplasm of 
endothelial origin. Since then, HHV-8 has been identified as the etiologic agent of all 
epidemiologic forms of KS, including classical, endemic African, iatrogenic and AIDS 
types. In addition,  HHV-8 has been implicated in the pathogenesis of other neoplastic 
disorders affecting immunocompromised hosts: primary effusion lymphoma (PEL, a 
rare form of B-cell lymphoma)
6
, multicentric Castleman disease (MCD, a B-cell 
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lymphoproliferative disease)
7
, other lymphoproliferative disorders affecting patients 
infected with HIV
8
, and neoplastic complications in patients after transplantation
9
. 
 
 
2.1.  Structure of human herpesvirus 8 
HHV-8 has the typical morphology of the herpesviruses. 
The envelope contains proteins of cellular origin and virus-specific glycoproteins, such 
as gB, gM, gH and K8.1. 
The tegument is an amorphous asymmetric proteinaceous layer between envelope and 
capsid and contains proteins encoded by ORFs 19, 63, 64, 67, 75. 
Each capsid, 125 nm in diameter, contains 12 pentons and 150 hexons which are 
interconnected by 320 triplexes. These capsomers or structural components are arranged 
in a icosahedral lattice with 20 triangular faces. Each asymmetric unit (one-third of a 
triangular face) of the capsid contains one-fifth of a penton at the vertex. Several 
proteins are involved in capsid assembling: the major capsid protein (MCP), three 
capsid proteins encoded by ORF62, ORF26, ORF65 and a protease encoded by ORF17. 
Hexons and pentons contain 5 or 6 MCPs, and triplexes contain ORF62 monomer and 
ORF26 dimer
10
. 
The core contains the linear double stranded DNA.  
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Figure 6: Structural comparison of HHV-8 capsid and HSV-1 B capsid. The two capsid maps are 
radially coloured and are shown in a montage as viewed along the icosahedral threefold axis. One 
penton (5), three types of hexon (P, E, and C), and six types of triplexes (Ta to Tf) are labelled. 
 
 
2.2. HHV-8 genome structure 
In the viral capsid, HHV-8 DNA is linear and double stranded, but upon infection of the 
host cell and release from the viral capsid, it circularizes. Reports of the length of the 
HHV-8 genome have been complicated by its numerous, hard-to-sequence, terminal 
repeats. Renne et al.
11
 reported a length of 170 kilobases (Kb) but Moore et al.
12
 
suggested a length of 270 Kb after analysis with clamped homogeneous electric field 
(CHEF) gel electrophoresis.  
Base pair composition on average across the HHV-8 genome is 59% G/C; however, this 
content can vary in specific areas across the genome.  
HHV-8 possesses a long unique region (LUR) of approximately 145 Kb, containing all 
the known ORFs (open reading frame), flanked by terminal repeats (TRs). Varying 
amounts of TR lengths have been observed in the different virus isolates. These repeats 
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are 801 base pairs in length with 85% G/C content, and have packaging and cleavage 
signals
12
. The LUR is similar to HVS and at least 66 ORFs have homology with the 
HSV genes. New genes are still being discovered through transcription experiments 
with alternative splicing. A "K" prefix denotes no genetic homology to any HVS genes 
(K1–K15).  
 
       
 
Figure 7: HHV-8 genome. The genome consists of a long unique region (145 kb) encoding for over 
80 ORFs, surrounded by terminal repeats regions. 
 
 
 
HHV-8 possesses approximately 26 core genes, shared and highly conserved across the 
alpha-, beta-, and gammaherpesviruses. These genes are in seven basic gene blocks, but 
the order and orientation can differ between subfamilies. These genes include those for 
gene regulation, nucleotide metabolism, DNA replication (polymerase ORF9 and 
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thymidin kinase ORF21), and virion maturation and structure (envelope glycoproteins: 
ORF8, ORF22, ORF38). 
HHV-8 encodes several ORFs homologous to cellular genes (at least 12), not shared by 
other human herpesviruses
13
. These genes seem to have been acquired from human 
cellular cDNA as evidenced by the lack of introns. Some retain host function, or have 
been modified to be constitutively active; an example of this is the viral cyclin-D 
gene
14
. Cellular homologs related to known oncogenes have been identified in HHV-8, 
including genes encoding viral Bcl-2 (ORF16), cyclin D (ORF72), interleukin-6 (K2), 
G-protein-coupled receptor (ORF74), and ribonucleotide reductase (ORF2).  
 
 
 
 
Figure 8: HHV-8 episome. 
 
 
 
23 
 
Other genes have homologues in other members of the RDV genus, such as v-cyclin 
(ORF72), latency-associated-nuclear antigen (LANA, ORF73), viral G-protein coupled 
receptor (ORF74). A number of other genes encoding for capsid protein have been 
identified, including ORF25, ORF26, and ORF65
13
. In addition to virion structural 
proteins and genes involved in virus replication, HHV-8 has genes and regulatory 
components (e.g. ORFs K3, K4 and K5) that interact with the host immune system, 
presumably to counteract cellular host defenses
15
. 
 
 
2.3.  Replication cycle of HHV-8 
Like other herpesviruses, HHV-8 genome structure and gene expression pattern varies 
depending on the replication state. The lytic phase consists of 6 steps: 
1. Binding to the cell surface mediated by glycoproteins B and K8.1, encoded by 
ORF8 and K8.1
16
. HHV-8 can use multiple receptor for infection of target cells, and 
these receptors differ according to the cell type. HHV-8 utilizes the ubiquitous cell 
surface heparan sulphate (HS) proteoglycan to bind several target cells (e.g. B 
lymphocytes). Glycoprotein B also interacts with the host cell surface alpha3-beta1-
integrin, a heterodimeric receptor containing transmembrane subunits. Another cellular 
receptor used is the dentritic cell specific intracellular adhesion molecule-3 (ICAM-3) 
for the binding to the myeloid dendritic cells and macrophages. Moreover, HHV-8 
utilizes the transporter protein xCT for entry into cells (but not into the B cells); xCT 
molecule is a part of the membrane glycoprotein CD98 complex.  
2. Fusion between envelope and plasma membrane. The binding between cellular 
receptors and HHV-8 glycoproteins leads to induction of the host signal cascades 
critical for maintenance of viral gene expression, such as protein kinase C (PKC), 
phosphatidylinositol 3-kinase (PI3K), and nuclear factor kB (NF-kB). In fact, HHV-8 
reprogrammes the elements of host cell transcriptional machinery that are involved in 
regulating a variety of processes (apoptosis, cell cycle regulation, signalling, 
inflammatory response and angiogenesis).  
3. Uncoating: capsid degradation by cellular enzymes and viral genome transfer to 
the cytoplasm. 
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Figure 9: Representation of the first three phases of early events of HHV-8 infection of target cells. 
 
 
4. Transcription: viral genome migrates to the nucleus and regulator genes are 
transcribed by host RNA polymerase. mRNAs are translated in virus-specific proteins, 
able to block cellular synthesis and to start viral replication. Lytic gene expression 
begins with transcription of immediate-early (IE) genes that regulate the synthesis of 
other viral genes. Some of the genes transcribed in this step are: ORF6, coding the 
major DNA binding protein (MDBP), ORFs 9, 56, 59, encoding the DNA polymerase 
and ORFs 40, 41, 44 (helicase/primase complex). Expression of IE genes occurs 
independent of viral replication, and afterwards, early and late genes are expressed.  
The early genes (E) expression is activated by IE genes within 24 hours after infection 
or viral reactivation. Early genes encode proteins involved in viral DNA replication, 
nucleotides metabolism, virus assembly. Some early genes are: K2-5, T1.1, ORFs2, 41, 
59, 70, 74. 
Expression of late genes (L) begins after viral DNA replication. They encode structural 
proteins involved in virus assembly, such as glycoproteins B and H (ORF8 and ORF22), 
capsid proteins (ORFs 25, 26), the small viral capsid antigen (ORF65). 
5. Assembly: transcription of genes coding structural proteins and production of 
viral particle. ORFs26 and 29 proteins are responsible for capsid assembly and viral 
DNA packaging. 
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6. The viral particles bud through the inner lamella of the nuclear membrane which 
has been modified by the insertion of viral glycoproteins and leave the cell via 
exocytosis. 
 
 
Figure 10: Representation of the last phases of the replication cycle of HHV-8. 
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After initial infection, HHV-8 may establish lifelong latency. Throughout latency, viral 
gene expression is tightly regulated and only a few viral genes are expressed. The latent 
HHV-8 genome is circularized by joining of GC rich terminal repeats (TRs) at the ends 
of the viral genome to form an extrachromosomal circular episome
17
. The latency 
associated nuclear antigen (LANA) regulates episome replication by host cell 
machinery
18
. LANA is a phosphoprotein expressed in latently infected cells and 
promotes the maintenance of latency by associating with the ORF50 promoter
19
 or 
binding cellular factors which normally interact with ORF50. HHV-8 infection can be 
reactivated from latency and the lytic gene expression may restart. 
 
 
2.4. Transactivator genes of HHV-8 
Two immediate-early genes play a key role in the reactivation from latent phase to lytic 
phase: ORF50 and ORF57. 
 ORF50 
ORF50 is an immediate early gene whose product is the major transcriptional 
transactivator and his activity is required for viral reactivation by all known chemical 
inducer (e.g. tetradecanoyl phorbol acetate, TPA). The ORF50 gene is rapidly 
expressed, within 2 to 4 h after induction. 
ORF50 belongs to the family of R transactivators, highly conserved among 
herpesviruses and is related to immediate-early transcriptional activator proteins of 
other gammaherpesviruses, such as ORF50a encoded by Herpesvirus saimiri and Rta 
encoded by the BRLF1 ORF of Epstein-Barr virus
20
.  
During latency, ORF50 expression is repressed; however, ORF50 may be activated by 
physiological conditions, such as hypoxia, or by pharmaceutical agents and the 
activation triggers the start of the lytic replication cascade. 
The genomic sequence of ORF50 is characterized by 5 exons and 4 introns and 
transcribes an mRNA of 3,6 Kb. The transcript initiates at position 71560, 23 nts 
downstream a potential TATA box; its first AUG is located at position 71596. 
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Figure 11: Schematic representation of ORF50 protein. 
 
 
The ORF50 transcript encodes a 691 aa protein (110 kDa) located in the nucleus during 
the latent phase for the presence of two nuclear localization signals (NLSs). The N-
terminus 272 amino acids of ORF50 binds independently to HHV-8 promoters and 
mediates sequence-specific DNA binding; N-terminal region is followed by a leucine 
zipper domain. The C-terminal domain contains multiple charged amino acids 
alternated with repeated bulky hydrophobic residues, a primary structure conserved in 
many eukaryotic transcriptional activation domains. The C-terminus is sufficient to 
activate transcription when targeted to promoters with a heterologous DNA binding 
domain
21
. 
This region contains four overlapping domains termed activation domains (AD1, AD2, 
AD3, AD4), sharing significant homology to the R proteins encoded by other gamma-
herpesviruses. 
Analysis of the ORF50 amino acids sequence reveals multiple sites of phosphorilation, 
including a C-terminal region rich in serines and threonines, and 20 other consensus 
sites for phosphorilation by serine-threonine kinase and protein kinase C (PKC). 
R response elements (RREs) have been identified within several lytic gene promoters. 
The response element contains a 12-bp palindrome with additional sequences flanking 
the palindrome which are also required for both DNA binding and activation by ORF50. 
The ORF50 protein binds directly to this palindromic sequence, and the N-terminal 272 
aa is sufficient for binding in vitro. ORF50 can directly transactivate the early gene 
promoters
22
.  
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The ORF50-responsive promoters include the following: ORF 6 (single-stranded DNA 
binding protein), ORF21 (thymidine kinase [TK]), ORF57 (posttranscriptional 
activator), ORF59 (DNA polymerase associated processivity factor), K8 (K-bZip), K9 
(viral interferon response factor), K12 (kaposin), and nut-1 or PAN or T1.1 
(polyadenylated nuclear RNA)
23
. 
Furthermore, recent studies suggest autoactivation of ORF50 by interaction with the 
cellular protein octamer-1 (oct-1) and an intact octamer element that is located 
approximately 200 bp upstream of the ORF50 transcription start site
24
. 
Expression of ORF50 reactivates viral lytic cycle in cells containing the virus in a latent 
phase
25
, and is also able to activate heterologous viral promoters such as LTR HIV, 
synergizing with Tat
26
. This molecular transactivation increases cellular susceptibility to 
HIV infection and could have clinical consequences in patients co-infected with HHV-8 
and HIV. 
The constitutive expression of ORF50 in stable clones increases expression of several 
cellular transcription factors, including activating transcriptional factor-4 (ATF4) 
(Unpublished data). 
 ORF57  
ORF57 is a lytic gene expressed between 2 and 4 h after activation of the lytic phase, 
immediately following the appearance of ORF50 transcripts but prior to most early 
mRNAs
21
.  
ORF57 is homologous to known posttranscriptional regulators in other herpesviruses. 
One of these, ICP27 of HSV is a regulator whose functions include downregulation of 
intron containing transcripts and upregulation of some late messages. ICP27 is essential 
for lytic viral replication, is required for inhibition of host cell splicing and shuttles from 
the nucleus to the cytoplasm to promote the export of intronless viral RNAs
27
. The other 
gammaherpesviruses, EBV and herpesvirus saimiri, also encode ICP27 homologs. 
ORF57 gene is positioned in a unique long region of the HHV-8 genome and is flanked 
by ORF56 (primase) and K9 (viral interferon regulatory factor, vIRF) genes. ORF56 
and ORF57 have their own promoter to initiate transcription, but they share the same 
polyadenilation signal downstream of ORF57.  
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Figure 12: Schematic diagram of ORF57 gene in the context of HHV-8 genome. 
 
 
ORF57 contains two coding exons and a single 108 bp intron. The exon 1 is relatively 
small, 114 nts, and has four ATG codons, clustered within a region of 33 nucleotides, in 
frame with each other and with the first exon and separated from it by a single stop 
codon. The intron is 109 nts in size and contains consensus splice donor and acceptor 
sites. The exon 2 is about 1,4 kb long. The transcriptional start site (TSS) is located at nt 
82003
27
 and polyA signal starts at nt 83608. A TATA box 24 bp is identified upstream 
the TSS as well as several consensus transcription factor binding sites (NF-kB, AP-1, 
Oct-1), and at least four R responsive elements involved in the transcriptional activation 
by ORF50. 
ORF57 expression is highly dependent on ORF50, and a RRE in the ORF57 promoter is 
responsible for ORF57 binding.  
ORF57 is expressed predominantly in the nucleus and nuclear localization is driven by 
three independent nuclear localization signals (NLS) that form a cluster in the N-
terminal.  
ORF57 encodes a protein of 455 aa residues. 
Analyses of amino acid sequence reveals several structural and functional motifs. The 
N-terminus contains a long stretch of arginine residues, two separate RGG-motifs, 
which are typical of RNA-binding proteins and four serine/arginine dipeptides, 
characteristic of SR proteins, the major cellular splicing factors. The three NLSs overlap 
the arginine rich region. 
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The C terminus of ORF57 is enriched in leucine residues and contains a leucine zipper 
motif, typical of cellular transcriprion factors. The C-terminus also contains the zinc-
finger-like motif. 
ORF57 promotes the expression of HHV-8 intronless genes, including several viral 
early and late genes, such as ORF59, T1.1 (PAN or nut-1), gB, MPC. ORF59 is an early 
gene encoding a viral DNA polymerase processivity factor involved in viral DNA 
replication. T1.1 is a non-coding RNA that accumulates at unusually high levels in the 
nucleus of lytically infected cells. 
ORF50 and ORF57 have a synergic activity that is promoter specific: expression of 
some promoters that are upregulated by ORF50 can be synergistically enhanced by 
coexpression with ORF57. This synergy results from a post-translational enhancement 
of the transcriptional activity of ORF50. ORF57 transactivates specific viral promoters 
in synergy with ORF50, such as promoters of T1.1, ori-Lyt and Kaposin. ORF57 
interacts with ORF50 via its N-terminal region and the central region of ORF50. 
 
 
2.5. Epidemiology and transmission of HHV-8 
The serologic prevalence of HHV-8 infection has been explored in most continents 
worldwide and in different populations with different levels of risk of HHV-8 infection. 
It should be noted that the comparisons of prevalence are limited by the fact that either 
antibodies to latent or lytic HHV-8 antigens were detected and by the test formats used. 
Several studies have confirmed that there is a low seroprevalence in central and 
northern Europe, North America and most of Asia, intermediate prevalence in the 
Middle East and Mediterranean, and high prevalence in southern Africa. 
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Figure 13: Worldwide geographic distribution of HHV-8 infection. 
 
 
The virus, first thought to be transmitted only sexually, is now also considered 
transmissible through low risk or more casual behaviours. Important risk factors for 
transmission of the virus are a spouse's seropositivity and maternal seropositivity. Of all 
anatomic sites, HHV-8 DNA is found most frequently in saliva, which also has higher 
viral concentrations than other secretions
28
. For this reason, it has been hypothesized 
that saliva could be the route of casual transfer of infectious virus among family 
members.  
Other possible transmissions are blood-borne and organ transplantation. 
 
 
2.6. HHV-8 pathogenesis 
Human herpesvirus 8 is associated with proliferative disorders including Kaposi’s 
sarcoma (KS), multicentric Castleman disease (MCD), primary effusion lymphoma 
(PEL), and other lymphoadenopathologies. 
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HHV-8 induces the formation of neoplasias in natural or experimental hosts, and 
reactivation from latency is essential for this activity. 
Latent viral proteins, such as vFLIP and LANA, inactivate tumour suppressors and 
block apoptosis
29
.  
However, lytic replication is also important for transmission of the virus in the 
population and in the pathogenesis of KS. HHV-8 vIL-6 is highly expressed during the 
lytic cycle, and promotes cellular growth and angiogenesis, while protecting against 
apoptosis
30
.  Additional evidence for the importance of lytic replication includes the fact 
that inhibition of active HHV-8 replication by gancyclovir reduces the incidence of 
HHV-8 in HIV-infected individuals
31
. 
 
                      
 
Figure 14: Cellular transformation after HHV-8 infection. 
 
 
 Kaposi’s sarcoma 
KS was first described by Moritz Kaposi in the 1870s
32
 and was described as an 
aggressive tumour affecting patients younger than those currently observed. For all 
epidemiological forms of KS, the tumour presents as an highly vascularised neoplasm 
that can be polyclonal, oligoclonal, or monoclonal. Its antigenic profile suggests either 
 
 
33 
 
endothelial, lymphoendothelial, or macrophage origins
8
. All forms of KS lesions 
contain a variety of cell types, including endothelium, extravasated erythrocytes, 
infiltrating inflammatory cells, and characteristic “spindle” cells of endothelial origin33. 
The spindle cells express both endothelial and macrophagic markers.  
Extensive and aberrant neoangiogenesis in KS lesions is accompanied by elevated 
levels of many cytokines, including basic fibroblast growth factor (bFGF), interleukin-1 
(IL-1), IL-6, IL-8, platelet-derived growth factor (PDGF), tumour necrosis factor 
(TNF), gamma interferon (IFN-), and vascular endothelial growth factor (VEGF). 
Many of these cytokines are secreted by spindle cells, are essential for spindle cell 
viability in culture, and are themselves proangiogenic.  
HIV infection increases the risk for development of KS, and therefore, the incidence of 
KS has increased substantially during the HIV pandemic, particularly in younger HIV-
infected patients
34
. 
 
 
 
Figure 15: Cutaneous and visceral manifestations of Kaposi’s sarcoma. 
 
 
Four forms of Kaposi’s sarcoma are known, differentiated on clinical parameters and 
epidemiology:  
Classic KS: is an indolent tumour affecting the elderly population, preferentially men, in 
Mediterranean countries. The lesions tend to be found in the lower extremities and the 
disease, due to its non-aggressive course, usually does not kill those afflicted.  
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AIDS-KS: in the context of the acquired immunodeficiency syndrome (AIDS), KS is the 
most common malignancy and is an AIDS defining illness
35
. AIDS-KS is a more 
aggressive tumour than classic KS and can disseminate into the viscera with a greater 
likelihood of death. It presents more often multifocally and more frequently on the 
upper body and head regions. 
Endemic KS: HHV-8 was prevalent in Africa prior to the HIV epidemic. Prior to HIV 
coinfections, endemic KS affected men with an average age of 35 and very young 
children
36
. HIV coinfection has raised the prevalence of KS significantly in Africa, 
where endemic KS is found more often in women and children than in other areas of the 
world
37
.  
Iatrogenic KS: Immunosuppression, as that occurring in transplant recipients, is known 
to facilitate reactivation of herpesviruses and therefore transplant patients under 
immunosuppressive therapy can develop KS. Withdrawal of the therapy can cause the 
KS to regress
38
.  
 Multicentric Castleman disease 
MCD is a rare polyclonal B-cell angiolymphoproliferative disorder. Most of the B-cells 
in the tumour are not infected with HHV-8, and the HHV-8 infected cells are primarily 
located in the mantel zone of the lymphatic follicle. It is thought that uninfected cells 
are recruited into the tumour through HHV-8 paracrine mechanisms, such as vIL-6, a 
known growth factor for the tumour. More than 90% of AIDS patients with MCD are 
HHV-8 positive, whereas MCD in the context of no HIV infection has a HHV-8 
prevalence of approximately 40%
39
.  
 Primary effusion lymphoma 
First identified as a subset of body-cavity-based lymphomas (BCBL), PELs contain 
HHV-8 DNA sequences
6
. These lymphomas are distinct from malignancies that cause 
other body cavity effusions. PEL cell lines have 50–150 copies of HHV-8 episomes per 
cell
40
. 
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2.7.  HHV-8 and angiogenesis 
The effects of acute HHV-8 infection on endothelial cell functions, induction of 
angiogenesis, and triggering of inflammatory processes are still largely unknown. 
In our laboratory, we demonstrated that HHV-8 selectively triggers the expression and 
secretion of high levels of monocyte chemoattractant protein 1 (MCP-1). We also found 
that this event is accompanied by virus-induced capillary-like structure formation at a 
very early stage of acute infection
41
. 
 
 
 
Figure 16: HUVEC monolayer not infected or infected with HHV-8 
41
. 
 
 
The MCP-1 expression is controlled by the nuclear factor kB (NF-kB), that induces the 
expression of chemokines promoting cell migration and angiogenesis, such as IL-8 and 
vascular endothelial growth factor (VEGF), several matrix metalloproteinases (MMPs) 
that promote tumour invasion of surrounding tissue. NF-kB is a critical regulator of the 
immediate early response to HHV-8, playing an important role in promoting 
inflammation, in the control of cell proliferation and survival, and in the regulation of 
virus replication. Several studies show that transfection of different HHV-8 genes 
results in NF-kB activation in different cell types, and in our laboratory we 
demonstrated that HHV-8 acute infection induces NF-kB activation in endothelial cells. 
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The human MCP-1 gene contains 2 NF-kB-binding sites in the enhancer region. The kB 
binding sites are required for TPA-induced expression. In HHV-8 infection we observed 
that the NF-kB pathway is involved in the enhancement of MCP-1 expression and is 
required for maximal production of the chemokine. However, mutations in both NF-kB 
sites in the enhancer region did not result in the complete loss of promoter induction in 
HHV-8 infected cells, and inhibitors of NF-kB do not prevent MCP-1 activation 
following HHV-8 infection suggesting that at least another signalling pathway may be 
involved in the control of MCP-1 expression in the course of acute HHV-8 infection. 
 
 
3. The cellular activating transcription factor 4 
 
ATF4 (also called cAMP responsive element binding 2, CREB2) belongs to the 
ATF/CREB family of transcription factors that represent a large group of basic region-
leucine zipper (bZip) proteins. The basic region of the bZIP protein interacts with DNA, 
and they dimerize by their leucine zipper domains forming homodimers, heterodimers 
or both
42
. 
CREB/ATF family members include ATF1 (also known as TREB36), CREB/CREM, 
CREB314 (also known as Aibzip or Atce1), CREB-H, ATF2 (also known as CRE-
BP1), ATF3, ATF4, ATF6, ATF7, B-ATF and ATFX (also known as ATF5). 
ATF4 gene is in chromosome 22 at the cytogenetic band 22q13.1, located at 
38,241,069–38,243,191 bp, with a genomic size of 2122 and is constitutively expressed 
in many cells. 
The structure of human ATF4 mRNA includes three short open reading frames (uORFs) 
in the 5’UTR that precede the functional coding sequence43 and are out of frame with 
the main protein-coding region. The organization of the 5’UTR uORFs in ATF4 is 
essential for the response of ATF4 to stress such as ER stress and hypoxia. 
ATF4 protein consists of 351 amino acids. The protein is structured into several 
domains/motifs that are essential for ATF4 homo/heterodimerization and DNA binding. 
A transcriptional activation domain has been located at the N-terminus of ATF4
44
. 
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Figure 17: Representation of ATF4. 
 
 
The mammalian ATF4 can form a homodimer, and heterodimers with members of the 
AP-1 and C/EBP family of proteins, including Fos
42
 and Jun
45
, and several C/EBP 
proteins
46
. ATF4 has a very short half-life of about 30-60 minutes. 
ATF4 has several interacting partners, which include p300
47
, RNA polymerase II 
subunit RPB3
48
, ZIP kinase, a serine/threonine kinase, which mediates apoptosis
49
, 
HTLV1 transactivator Tax, which activates the expression of viral mRNA through a 
three 21 bp repeat enhancer located within the HTLV-1 LTR
50
. Tax transactivates the 
HTLV-1 promoter via the Tax responsive elements that contain the consensus 
ATF/CRE core sequence. ATF4 enhances the ability of Tax to transactivate the HTLV-
1 promoter. The numerous dimerization and interaction partners determine the diverse 
functions of ATF4. 
ATF4 can function as a transcriptional activator, as well as a repressor. It is a stress 
responsive gene, which is upregulated by several factors/stressors, including oxygen 
deprivation (hypoxia/anoxia), amino acid deprivation, endoplasmic reticulum stress (ER 
stress), oxidative stress, and by the growth factor heregulin
51
. 
In mammalian cells, hypoxia/anoxia and perturbation of ER homeostasis induces a 
complex transcriptional program and triggers a reduction in protein translation (UPR: 
unfolded protein response). A central mediator of this translational response to anoxia is 
phosphorylation of the eukaryotic initiation factor 2 (eIF2) by PERK protein kinase. 
Although the phosphorylation of eIF2 results in global translational reduction, it 
specifically increases the translation of ATF4 mRNA
43
. The various stress signals 
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integrate in a common pathway of increased translation of ATF4, which subsequently 
ensures supply of amino acids for protein biosynthesis and protects cells against 
oxidative stress, by modulating a number of genes involved in mitochondrial function 
(e.g., Lon mitochondrial protease homologue), amino acid metabolism and transport 
(e.g., asparagine synthetase), as well as in redox chemistry (e.g., NADH cytochrome B5 
reductase homolog)
52
. As a result of metabolic and ER stress that activate the PERK 
pathway of translational inhibition, ATF4 initiates a feedback regulatory loop to ensure 
the transient nature of protein synthesis inhibition. ATF4 induces GADD34 
transcription, a component of the phosphatase complex that dephosphorylates eIF-
2alpha. 
Some of the genes that are induced by ATF4 include receptor activator of nuclear 
factor-kappa B (RANK) ligand (RANKL), osteocalcin, E-selectin, VEGF, Gadd153, 
gadd34, asparagine-synthesase, TRB3, and several genes involved in mitochondrial 
function, amino acid metabolism and redox chemistry
52
.  
 
 
 
Figure 18: Three proximal sensors IRE1, PERK and ATF6 regulate the UPR through their respective 
signalling cascades. 
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One important stress factor relevant to cancer progression is hypoxia and more 
extremely, anoxia. Tumour hypoxia/anoxia is associated with a more aggressive clinical 
phenotype, and ATF4 protein has been observed to be in much greater levels in primary 
human tumours compared to normal tissues
53
. 
ATF4 induces VEGF and E-selectin which may be associated with increased metastasis. 
Since ATF4 protein has shown to be present at greater levels in cancer compared to 
normal tissue, and it is upregulated by signals of the tumour microenvironment such as 
hypoxia/anoxia, oxidative stress, and ER stress, it could potentially serve as a specific 
target in cancer therapy. As a target ATF4 is attractive because it is also potentially 
involved in angiogenesis and adaptation of cancer cells to hypoxia/anoxia, which are 
major problems in cancer progression. The induction of VEGF (vascular endothelial 
growth factor) has a key role in angiogenesis, and preliminary study in our laboratory 
demonstrate that transfection of ATF4 induces capillary-like structure formation in 
vitro. 
Many viruses have been shown to induce ER stress and activate the UPR: these include 
three members of the flavivirus, C hepatitis and HCMV. Viral infection induces the cell 
response to stress, which should lead to an attenuation of viral replication. However, 
some aspects of the UPR can be regulated and limited by the virus. For example, 
infection with HCMV (betaherpesvirus) induces the UPR by regulating specifically 
three signalling pathways: PERK, ATF6 (activating transcription factor 6) and Ire-1
54
.  
Cells infected with this betaherpesvirus show an increase in ATF4 protein levels, 
leading to the activation of genes involved in metabolism and redox reactions and 
helping the virus to maintain a cellular environment permissive to infection. 
Studies demonstrate that also HHV-8 can interact with ATF4. LANA, the latency 
associated nuclear antigen, encoded by ORF73, represses the transcriptional activation 
activity of ATF4 and the interaction requires the bZIP domain of ATF4. Repression by 
LANA is independent from the DNA-binding ability of ATF4
55
. 
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AIM OF THE RESEARCH 
 
 
Human herpesvirus 8 is the primary etiologic agent of Kaposi’s sarcoma, a highly 
vascularised neoplasm of endothelial origin characterized by inflammation, 
neoangiogenesis, and by the presence of characteristic spindle cells. 
HHV-8 infection of endothelial cells causes changes in cellular phenotype and leads 
to capillary-like structures formation. This angiogenic activity of HHV-8 is due to 
the activation of NF-kB and the subsequent induction of MCP-1 synthesis. 
MCP-1 is a chemokine produced by macrophages and endothelial cells in response to 
different stimuli, and is a direct mediator of angiogenesis. The MCP-1 promoter 
contains an enhancer region with two NF-kB sites. MCP-1 production after HHV-8 
infection is accompanied by virus-induced capillary-like structure formation in 
endothelial cells, and HHV-8-induced angiogenesis is MCP-1 dependent. 
Previous studies demonstrate that HHV-8 activates the MCP-1 promoter also in 
absence of the enhancer region containing the NF-kB binding sites, in fact, mutations 
in NF-kB sites do not result in a complete loss of MCP-1 transcription. Moreover, 
treatment with NF-kB-inhibitors does not prevent MCP-1 activation in HHV-8 
infected cells.  
Therefore, HHV-8 activation of MCP-1 is not completely dependent on NF-kB 
induction and another cellular factor is involved.  
A potential candidate is the cellular activating transcription factor 4 (ATF4), a stress 
responsive gene. ATF4 is upregulated in several condition, including ER-stress, viral 
infection (e.g. CMV) and in tumours.  
Previous data obtained by gene array in stable Jurkat cell clones transfected with 
ORF50 gene (major transactivator of HHV-8), indicated that HHV-8 upregulates 
ATF4. 
The aim of the research was therefore to determine whether the viral infection of 
HHV-8 increases the expression of the transcription factor ATF4 and clarify if this 
increase is functional for the replication of HHV-8. The results showed that HHV-8 
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(and ORF50) causes a significant increase of ATF4, and that this increase leads to 
increased virus replication in infected cells. 
ATF4 is not able to reactivate HHV-8 from latency, being unable to activate the 
major gene promoters. This “indirect” effect on HHV-8 activity can be explained by 
investigation of interactions between ATF4 and MCP-1. In fact, we found that ATF4 
activates the MCP-1 promoter, and this activity is NF-kB-independent. 
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MATERIALS AND METHODS 
 
 
1. Cell cultures 
The B cell lines BC-3 and BCBL-1, derived from PEL and chronically infected with 
HHV-8, were used as representative of HHV-8 target of infection. Lymphoid T 
(Jurkat cells) and B cell lines were grown in RPMI medium (Gibco) supplemented 
with 10% inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 mg/ml streptomycin.  
HeLa cell line (human cervix carcinoma cells) and 293 cell line (human embryonic 
kidney cells) were grown in Dulbecco’s Modified Eagle medium (Gibco) 
supplemented with 10% inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
100 U/ml penicillin and 100 mg/ml streptomycin. 
All cells were cultured at 37°C in the presence of 5% CO2. 
 
 
2. Plasmids 
Transfection experiments were performed using recombinant plasmids pCR-50sp, 
pGL-PR57, pGL-PR50, pGL-PRT1.1, pGLM-PRM, pGLM-ENH, pGLM-
MA1MA2, pRL-SV40 and pCG-ATF4.  
Spliced forms of ORF50 were cloned in the expression vector pCR3.1-Uni 
(Invitrogen) in our laboratory
25
. Briefly, spliced genes were obtained from TPA-
activated BCBL-1 cells by specific retrotranscription of polyA RNA followed by 
PCR amplification. Amplified fragments were sequenced to verify their integrity and 
were then inserted into the vector pCR3.1-Uni to obtain the recombinant plasmid 
pCR-50sp. 
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Figure 19: pCR3.1-Uni map. 
 
 
 
 
44 
 
HHV-8 gene promoters were cloned in the reporter vector pGL3-Basic in this 
laboratory
56
, containing the Firefly luciferase gene cloned under the transcriptional 
control of HHV-8 promoters. 
The MCP-1 promoter-luciferase constructs (provided by Dr. T. Yoshimura)
57
 contain 
the proximal promoter (pGLM-PRM), the proximal promoter and the distal enhancer 
(pGLM-ENH), the proximal promoter and the distal enhancer in which both NF-kB 
sites are mutated (pGLM-MA1MA2). 
 
 
 
Figure 20: Firefly luciferase pGL3-Basic vector. 
 
 
pRL-SV40 vector (Promega) was used as an internal transcriptional control, and 
contains the Renilla luciferase gene cloned under the transcriptional control of the 
SV40 virus promoter. 
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Figure 21: Renilla luciferase pRL-SV40 vector. 
 
 
pCG-ATF4 plasmid contains the ATF4 gene cloned under the transcriptional control 
of the CMV promoter
51
. 
 
 
3. Cell transfections 
Jurkat, BC-3 and BCBL-1 cells were seeded 24 hours before transfection to obtain 
optimal cellular density (10
6
 cells/mL) and 10
6 
cell samples were transfected with 1 
g of plasmid DNA by electroporation (Nucleofector, Amaxa), following the 
manufacturer’s instructions. This method permits to obtain high efficiency of 
transfection, carrying the exogenous DNA into the cells and directly into the nucleus. 
Efficiency of transfection determined in parallel samples by transfection with pmax- 
GFP plasmid (Amaxa). 
HeLa and 293 cells were seeded in 24-well plates 24 hours prior to transfection to 
obtain optimal confluence, then were transfected with g of plasmid DNA by 
GeneJuice Transfection Reagent (Novagen), based on polyamine formulation, 
following the manufacturer’s instructions. 
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4. Virus purification and cell infection  
Cell-free HHV-8 inoculum was obtained by stimulation of BC-3 cells for 3 days with 
20 ng/mL 12-O-tetradecanoyl-phorbol-13-acetate (TPA; Sigma). Cells were 
collected by centrifugation and lysed by rapid freezing and thawing followed by 
sonication (3 cycles of 5 seconds at medium power with 10-second intervals in a 
water bath sonicator). Cleared cellular content was added to culture supernatant, and 
virions were collected by centrifugation for 30 minutes at 20000 xg at 4°C.  
Virus particles were purified by density centrifugation on Optiprep self-forming 
gradients (Sentinel), at 58000 xg for 3,5 hours at 4°C. Purified virions were washed 
in phosphate buffered saline (PBS) and collected by centrifugation at 20000 xg for 
30 minutes at 4°C. 
Virions were suspended in sterile PBS containing 0,1% bovine serum albumin (BSA) 
and stored at -80°C until use. To obtain 1 mL of purified virus, 4^10
8
 BC-3 cells 
were stimulated. The same ratio between cells and final suspension volume was 
maintained in all virus preparations to avoid variations in virus concentration 
between different stocks. 
Virus particles were morphologically intact, and the preparation was cell debris-free, 
as assessed by electron microscope observation.  
Prior to use, virus stock was treated with DNase-I and RNase-A, to eliminate free 
viral nucleic acids eventually present in the preparation. 
Infectivity of virus preparation was evaluated by specifically designed infection 
experiments performed in different cell types, using PCR, rtPCR and 
immunofluorescence assays to evaluate virus presence, transcription, and expression 
of antigens.  
Quantification of virus genomes present in the stock preparation was obtained by 
real-time polymerase chain reaction (qPCR)
58
. 
HHV-8 DNA standard was obtained by serial dilutions of pCR-ORF26 plasmid 
containing a cloned fragment of HHV-8 DNA (ORF26, nucleotides 47127 to 47556). 
The absence of human gDNA was assessed by amplification of the -actin gene. The 
purified cell-free virus inoculum contained an average of 4,7^10
5
 copies of viral 
DNA/L. 
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T and B cells were seeded 24 hours before infection to obtain optimal density of 
10
6
cells/mL and then were infected with a m.o.i. (multiplicity of infection, referred 
to equivalent genomes) of 1:10. After 3 hours of absorption at 37°C, the HHV-8 
inoculum was removed, cells were washed with PBS and incubated in fresh medium. 
Cell samples were harvested at specific time points and processed for DNA or RNA 
extraction. 
 
 
5. DNA extraction 
Genomic DNA was extracted from 10
6
 cell samples. 
Cells were lysed in 500L lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM disodium 
EDTA pH 8.0, 10 mM NaCl, 0.6% SDS and 100 g/ml proteinase K) and incubated 
at 37°C for a minimum time of 4 hours. After three cycles of 
phenol:chloroform:isoamyl alcohol (25:24:1) extractions, DNA was recovered by 
ethanol precipitation, resuspended in sterile water, and RNase A was added to a final 
concentration of 100 g/ml. Following 1 hour incubation at 37°C, RNase A was 
removed by phenol extraction. After precipitation with ethanol, DNA pellets were 
dissolved in sterile water and stored at -20°C until PCR or qPCR analysis. 
DNA concentration was determined by reading optical density at 260 nm. 
 
 
6. RNA extraction and retrotranscription 
Total RNA was extracted with RNAzol B (Tel-Test), following the protocol 
provided by the manufacturer. Briefly, 10
6
 cell samples were lysed with RNAzol, 
then, chloroform in ratio 1:5 was added. The mixture was centrifuged 20 minutes at 
8500 xg and the aqueous phase was collected and RNA precipitated with 
isopropanol. After two washes with 75% ethanol and DNAse treatment (4 U/mg 
RNA, 3 x 20 min. at room temperature), RNA was precipitated with isopropanol 20 
minutes at 8500 xg at 4°C. RNA quality was checked by electrophoretic analysis on 
a 0.8% agarose gel. The absence of contaminating DNA was checked by PCR 
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amplification of human -actin gene before retrotranscription (RT-). Negative PCR 
results for -actin ensured that the RNA sample was completely free from DNA 
sequences. First strand cDNA synthesis was carried out with MuLV reverse 
transcriptase and random hexamer primers (Applied Biosystems), following the 
manufacturer’s instructions, retrotranscribing 2 g of total RNA from all the 
samples. The mixture was incubated for 1 hour at 42°C. Efficiency of 
retrotranscription was assessed by analysis of dilutions of cDNA with PCR specific 
for human -actin gene (RT+). 
 
 
7. PCR and rtPCR 
The presence and the level of transcription of HHV-8 were analyzed by PCR and 
reverse transcription PCR (rtPCR) amplification of the ORF26 and ORF50 genes. 
PCR amplification was performed using 100 ng total DNA or 200 ng total cDNA 
extracted from infected cells. Amplification of the housekeeping -actin gene was 
used as a control. The transcription of ATF4 was analysed by rtPCR amplification of 
the ATF4 gene. Specific primers and PCR conditions are described in Table 2. The 
absence of contaminating DNA was checked by PCR amplification of human -actin 
gene before retrotranscription. Negative PCR results for -actin ensured that the 
RNA sample was completely free from DNA sequences, and that positive 
amplification after retrotranscription was positively associated to viral transcripts. 
Particular care was taken to avoid sample-to-sample contamination: different rooms 
and dedicated equipment were used for DNA extraction and processing, for PCR set-
up and gel analyses, all pipette tips had filters for aerosol protection. 
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GENES  PRIMERS  SEQUENCES  AMPLICONS 
ORF50  ORF50-Forw 
ORF50-Rev  
5'-TTGGTGCGCTATGTGGTCTG-3‘ 
5'-GGAAGGTAGACCGGTTGGAA-3'  
420 bps 
ORF26  ORF26-Forw 
ORF26-Rev  
5'-GCCGAAAGGATTCCACCAT-3‘ 
5'-TCCGTGTTGTCTACGTCCAG-3'  
232 bps 
ATF4 ATF4-Forw 
ATF4-Rev 
5’-GTGGCCAAGCACTTCAAACC-3’ 
5’-GGAATGATCTGGAGTGGAGG-3’ 
414 bps 
b-actin  HACT-Forw  
HACT-Rev  
5’-TCACCCACACTGTGCCCATCT-3’ 
5’-GACTACCTCATGAAGATCCTCAC-3’ 
674 bps 
 
 
GENES 
 
CONDITIONS  
 
CYCLES 
 
[MgCl2] 
 
ORF50 
94°C  5min  
94°C  30 sec, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle  
72°C  10 min, 4°C >>>  
1 
35 
1 
 
2mM 
 
ORF26 
94°C  5min  
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle  
72°C  10 min, 4°C >>>  
1 
45 
1 
 
1.5 mM 
 
ATF4 
94°C  5min  
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle  
72°C  10 min, 4°C >>>  
1 
35 
1 
 
2mM 
 
b-actin 
94°C  5min  
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle  
72°C  10 min, 4°C >>>  
1 
30 
1 
 
1.25mM 
 
Table 2: Primer sets and thermal conditions used for PCR and rtPCR reactions. 
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8. Real time PCR (qPCR) 
Real time PCR or quantitative PCR (qPCR) was used to determine the amount of 
ORF26 and ATF4 genes. -actin housekeeping gene was used as internal control in 
order to normalize the results. 
qPCR using the TaqMan probes was performed using the 7700 ABI Prism (Applied 
Biosystems). 
The DNA or cDNA copy numbers were quantified by comparison with a 10-fold 
serial dilutions of known concentrations of pCG-ATF4 or pCR-ORF26 plasmids. 
The concentration of the standard DNA was assessed by spectrophotometer and 
plasmid copy numbers were calculated to prepare standard curves (10
7
 to 10 copies). 
Amplifications were carried out in a 50 L total volume containing 25 L 2X 
TaqMan Universal PCR Master Mix (Applied Biosystems), 5 L of primer and 
probes, and 20 L template. The target genes were amplified using TaqMan FAM-
labelled probe at the 5’-end and TAMRA quencher at the 3’-end. The -actin 
housekeeping gene was simultaneously amplified using a 5’-VIC-labelled probe. 
Primers and probes used are shown in Table 3. Concentrations of the primers and 
probes were 900 nM of each primer and 200 nM of each probe. 
The reaction conditions for all templates were 10 minutes at 95°C for enzyme 
activation, and 40 cycles with 15 seconds at 95°C for DNA denaturation and 1 
minute at 60°C for annealing and extension. Fluorescence data were collected in the 
primer elongation phase at 60°C.  
To normalise the data, the cycle threshold (Ct) values of the housekeeping gene were 
subtracted from the target gene Ct value of the sample. 
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GENES 
PRIMERS & 
PROBES 
 
SEQUENCES  
 
ORF26 
H8-Forward 
H8-Reverse 
H8-Probe 
5'-CTCGAATCCAACGGATTTGAC-3‘ 
5'-TGCTGCAGAATAGCGTGCC-3'    
5’-(6Fam) CCATGGTCGTGCCGCAGCA (Tamra)-3’ 
 
ATF4 
ATF4-Forward 
ATF4-Reverse 
ATF4-Probe 
5’-CCCCCCTAGTCCAGGAGACT-3’ 
5’-CTGGGAGATGGCCAATTGG-3’ 
5’-(6Fam) ATAAGCAGCCCCCCCAGACGG (Tamra)-3’ 
 
-actin 
h-ACT-Forward 
h-ACT-Reverse 
h-ACT-Probe 
5'-TCACCCACACTGTGCCCATCT-3'  
5'-GACTACCTCATGAAGATCCTCAC-3'  
5’-(Vic) ATGCCCTCCCCCATGCCATCCTGCGT (Tamra)-3’  
 
Table 3: Primer and probe sets used for real time PCR quantifications. 
 
 
9. Luciferase assay 
The Luciferase assay was performed using the Dual-Glo Luciferase Assay System 
(Promega). Luciferase and Renilla were used as co-reporters to measure gene 
expression. In order to generate luminescence Firefly luciferase requires luciferin, 
ATP, magnesium and molecular oxygen. Renilla luciferase requires coelenterazine 
and molecular oxygen.  
Cells were seeded into 24-well plates 24 hours prior to transfection, then, they were 
co-transfected with the reporter constructs, pRL-SV40, and with the expression 
plasmids. 48 hours post-transfection, Dual-Glo Luciferase Reagent was added to 
each well in ratio 1:1 with the medium and cells were transferred to 96-well plate. 
After at least 10 minutes of incubation, the firefly luminescence was measured. 
Following the first measurement, an equal volume of Dual-Glo Stop&Glo Reagent 
was added and after 10 minutes incubation, the Renilla luminescence was measured. 
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The results were expressed as Luciferase activity, normalized using the Renilla 
emission. 
 
 
10. Western blotting 
Cell samples (1-2^10
6
) were harvested and centrifuged 2 minutes at 8000 xg. Pellets 
were resuspended in lysis buffer (6,7 M urea, 10 mM Tris-HCl pH 6.8, 5 mM DTT, 
1% SDS, 10% glycerol, protease inhibitors cocktail) and debris was eliminated by 
centrifugation. 6X loading buffer was added to 20 g cellular total lysated, and the 
mixture was subjected to 10% SDS-PAGE electrophoresis. Following 
electrophoresis, proteins were transferred in the Hibond-P PVDF-membrane 
(Amersham) in an electroblotter (Biorad). After transfer, the membrane was probed 
with the rabbit anti-ATF4 antibody (SantaCruz Biotechnology) 1:200 diluted, 90 
minutes at room temperature. After three washes, the membrane was incubated with 
the anti-rabbit HRP conjugated antibody (SantaCruz Biotechnology) 1:1000 diluted 
for 90 minutes at room temperature. After three washes the antibody was revealed by 
luminol staining (SuperSignal West Pico Chemiluminescent Substrate, Pierce). 
ATF4 molecular weight is 38 kDa. 
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RESULTS 
 
 
1. HHV-8 infection increases ATF4 expression 
Results previously obtained by gene array in stable clones of Jurkat cells transfected with 
plasmid pCR-ORF50sp indicated that the expression of transactivator ORF50 of HHV-8 
upregulates the transcription factor ATF4 (unpublished data). 
Based on this preliminary observation, we verified whether the infection with the entire 
HHV-8 could have the same effect on ATF4 expression. To study the effect of HHV-8 
infection we used the cell-free inoculum obtained in our laboratory to infect Jurkat cells in 
vitro and analyze the effect of the viral infection on ATF4 transcription. 
Briefly, Jurkat cells were seeded at optimal density (10
6
 cells/mL) 24 hours before 
infection and were then infected with HHV-8 (1:10 of m.o.i.) as described in Materials and 
Methods. Samples were then collected for analysis of cellular transcription of ATF4 at 
different times post-infection (p.i.) 0, 4, 8, 24 and 48 hours p.i.. 
Total RNA was extracted by organic solvent extraction (RNAzol) from each cell sample 
(10
6
 cells), and RNAs were treated with DNase to eliminate possible genomic DNA 
contamination. To verify the absence of DNA contamination, a PCR was carried out using 
200 ng of RNA as template (RT-) and amplifying the gene for β-actin, constitutively 
present and ubiquitous in the cells used (housekeeping gene). After verifying the absence 
of contaminating DNA, shown by the absence of amplification product, RNA was reverse-
transcribed into cDNA. ATF4 was amplified using the specific primers and temperature 
conditions described in Materials and Methods. ATF4 transcript was quantitated by semi-
quantitative rtPCR, performing PCR amplification reactions on 10-fold serially diluted 
cDNA templates. The absence of the amplification products identifies the dilution in which 
targets are below the sensitivity threshold. 
In parallel, the same dilutions of template were used to amplify the house-keeping β-actin 
gene as a control. PCR products were run in a 2% agarose gel and visualized by ethidium 
bromide staining. 
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Fig. 22 shows the results of the samples collected at 24, 48 hours p.i. and semi-quantitative 
rtPCR specific for β-actin, which is necessary in order to normalize the results obtained by 
rtPCR specific for ATF4. 
Infection with HHV-8 induces a 10-fold increase of ATF4 transcription at 24 hours and 48 
hours post infection, compared to control uninfected cells. 
 
 
 
 
 Figure 22: Semiquantitative rtPCR on ATF4 transcript and -actin in Jurkat cells HHV-8 infected or not 
infected; rtPCR products are ethidium bromide stained in 2% agarose gel. 
 
 
The results obtained by semi-quantitative rtPCR showed an increase in the ATF4 transcript 
induced by infection with HHV-8. To confirm these data, we repeated the experiments 
using the real-time PCR, to quantify more precisely ATF4 transcripts. Compared with 
PCR, the real-time PCR has an important advantage: the results are normalized with the 
simultaneous amplification of the housekeeping gene β-actin, avoiding errors due to over 
or underestimation of template. 
Twenty μl of cDNA-template (corresponding to 200 ng of total RNA) were amplified in 30 
μl of reaction mix, as described in Materials and Methods. 
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The results, summarized in Figure 23, showed that infection with HHV-8 causes an 
increase of the ATF4 transcript by approximately 1,3 fold at 8 hours p.i., 9,5 fold at 24 
hours p.i. and 6,7 fold at 48 hours p.i.. 
This result confirmed data obtained by semiquantitative rtPCR, showing a peak of 
upregulation at 24 hours p.i.. 
 
 
 
Figure 23: ATF4 transcription levels in Jurkat cells HHV-8-infected or not-infected at 8, 24 and 48 hours 
post infection, analysed by real time PCR. 
 
 
To determine whether infection with HHV-8 had effect also on the levels of ATF4 protein, 
a western blot analysis was performed using a monoclonal antibody anti-ATF4/CREB2 
(Santa Cruz Biotechnology). 20 g of total protein extract, derived from HHV-8 infected 
Jurkat cells, was electrophoretically separated, transferred to Hybond-P membrane 
(Amersham) and hybridized with the monoclonal antibody anti-ATF4. The results showed 
an increase of ATF4 protein levels in infected cells compared to non-infected. 
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Figure 24: Western blotting analysis of ATF4 protein levels in non-infected and HHV-8-infected Jurkat 
cells. 
 
 
2. ATF4 induces HHV-8 replication  
Based on the results showing the increase of ATF4 transcription after HHV-8 infection, we 
further investigated whether this increase was functional to viral replication and if the 
overexpression of ATF4 could have a positive effect on replication of HHV-8. 
To verify this hypothesis, Jurkat cells were transfected with pCG-ATF4 plasmid, 
containing the full length ATF4 gene cloned under the transcriptional control of early 
promoter of human cytomegalovirus (CMV). Jurkat cells were seeded at optimal 
confluence 24 hours before transfection. Cell samples of 2^10
6
 were transfected by 
nucleofection with 2 μg of pCG-ATF4 plasmid DNA. Control cells were nucleofected with 
2 μg of the vector pCR3.1-Uni, containing only the CMV early promoter. In parallel, to 
assess the transfection efficiency, cells were transfected with the pmax-GFP plasmid 
containing the gene encoding GFP (green fluorescent protein), cloned under the 
transcriptional control of early promoter of CMV. 24 hours post transfection, cells 
expressing GFP (green) compared to the number of total cells were more than 50%. 
The viability was verified by the exclusion assay Trypan Blue 24 hours after transfection, 
and was about 80%. 
8h       24h      48h
ATF4 protein (W.B.)
Jurkat + HHV-8
Jurkat
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To verify the production of ATF4 messenger, cell samples were analyzed by rtPCR 24 and 
48 hours after transfection. The results show the ability of the plasmid to produce a 100 
fold enhancement of ATF4 levels in the transfected cells (Fig. 25). 
 
 
 
Figure 25: Semiquantitative rtPCR on ATF4 transcripts in Jurkat transfected with pCG-ATF4 and in 
Jurkat transfected with “empty” vector pCR3.1-Uni, 24 hours post transfection. 
 
 
In order to investigate the effect of ATF4 overexpression on HHV-8, Jurkat cells were 
seeded at optimal confluence and were then transfected with pCG-ATF4 plasmid or with 
control pCR3.1-Uni empty vector. After verifying vitality and efficiency of transfection, 
cells were infected with HHV-8 (1:10 of m.o.i.). After 3 hours adsorption, the virus 
inoculum was removed. Cell samples were then collected at 0, 8, 24 and 48 hours p.i.. To 
evaluate the replication and transcription of HHV-8, respectively, DNA and RNA 
extracted from cells were analyzed. To investigate viral replication, total DNA was 
extracted from 10
6
 cell samples collected at different times p.i. and was used as template in 
real-time PCR to quantify the presence of virus by amplification of late viral ORF26 gene 
(using 1μg of DNA as template). The results showed that the overexpression of ATF4 
leads to a 15 fold increase in viral replication at 24 hours p.i., and 9,7 fold at 48h.  
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Figure 26: Analysis of ORF26 expression by real time PCR on DNA of HHV-8-infected Jurkat cells, 
tranfected with ATF4 plasmid or with pCR3.1 empty vector. Collection times were: 8, 24 and 48 hours. 
 
 
To investigate transcription of HHV-8 in presence or absence of ATF4, total RNA from 
cell samples was extracted, reverse transcribed to cDNA and analysed by rtPCR, searching 
for viral transcripts corresponding to ORF50 and ORF26 genes. As described above, rtPCR 
was performed using serial dilutions of template. In parallel, the same dilutions of template 
were amplified for the β-actin gene (housekeeping gene) as control. Amplification products 
were run in 2% agarose gel and ethidium bromide stained. Fig. 27 shows the results of 
rtPCR at 24 and 48 hours p.i.. 
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Figure 27: Analysis of ORF50 and ORF26 transcripts by semiquantitative rtPCR in Jurkat cells transfected 
with ATF4 plasmid and HHV-8 infected. 
 
 
The increase of HHV-8 ORF50 transcripts is evident at all times, whereas the increase of 
ORF26 is most evident at 48 hours p.i.. Two independent experiments were performed 
with samples in duplicate. The data show that the overexpression of ATF4 increases the 
HHV-8 transcription.  
 
 
3. The expression of ATF4 does not reactivate HHV-8 from latency 
The results obtained showed that ATF4 is able to increase replication of HHV-8 in infected 
cells. Based on this observation, we investigated whether ATF4 is also able to directly 
reactivate the productive cycle of HHV-8 in latently infected cells. 
For this purpose cell lines BC-3 and BCBL-1 were used, both derived from PEL, 
containing HHV-8 in a latent state. The reactivation of the virus can be obtained by 
treatment with phorbol esters, e.g. TPA, which is the method used to produce the cell-free 
viral inoculum used in the experiments of infection in vitro. Samples of 2^10
6
 BCBL-1 
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cells were transfected by nucleofection with 2 μg of pCG-ATF4 plasmid or pCR3.1-Uni 
empty vector. Samples were collected at different times (1, 2, 3 and 6 days) post-
transfection, and DNA was extracted to quantify viral genome by real time PCR specific 
for the viral gene ORF26 of HHV-8. As a positive control of reactivation, cells were 
stimulated with TPA (20 ng/ml). 
The results (Fig. 28) show that the expression of ATF4 does not induce viral reactivation, 
as proven by a similar amount of HHV-8 DNA molecules in control cells and in those 
transfected with ATF4. 
 
 
 
Figure 28: Real time PCR of BCBL-1 DNA. C-: untreated BCBL1 cells; TPA: cells treated with TPA 
(reactivation from latency); ATF4: cells transfected with pCG-ATF4 plasmid.  
 
 
In contrast, as expected, treatment with TPA (used as a positive control) reactivated viral 
replication, causing about 10 fold increase of viral genomes copy numbers into the cells. 
To verify that this “negative” result was not due to cell type used, we repeated the 
experiment with BC-3 cells, which also contain HHV-8 in a latent state. 
The results confirmed that nucleofection with ATF4 does not increase the number of 
genomes compared to cells transfected with empty plasmid, thus confirming that ATF4 is 
not able to directly induce the reactivation of HHV-8 (data not shown). 
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4. ATF4 does not activate HHV-8 promoters  
Because of the results of the in vitro HHV-8 infection showing that ATF4 promotes viral 
replication, we investigated whether ATF4 acts at transcriptional level, inducing the 
activation of major gene promoters of HHV-8, ORF50, ORF57 and T1.1 promoters. 
Jurkat cells were seeded at optimal density and then transfected with pCG-ATF4 plasmid 
and with reporter plasmids containing the reporter gene luc (encoding the luciferase 
enzyme of Firefly) cloned under the transcriptional control of different gene promoters 
(PR) of HHV-8: pGL-PR50 (ORF50 promoter), pGL-PR57 (ORF57 promoter), pGL-T1.1 
(T1.1 promoter that encodes a nuclear polyadenylation RNA, PAN mRNA, a non-coding 
transcript that represents the most abundant lytic cycle transcript). These plasmids were 
previously obtained in our laboratory
56
.  
Nucleofection was performed in duplicate on samples of 2^10
6
 cells with 2 μg total DNA 
consisting of: a fixed amount (500 ng) of reporter pGL-PR plasmid series of HHV-8, with 
different concentrations (500 ng, 1 g) of pCG-ATF4 plasmid or control vector pCR3.1-
Uni, and a constant concentration (500 ng) of pGL-SV40 reporter plasmid containing the 
luciferase reporter gene of Renilla. 
The Renilla luciferase is cloned under the transcriptional control of SV40 promoter and 
expresses an enzyme that acts at a different pH from the Firefly luciferase (respectively pH 
9-10 and pH 7.8): for this reason the two reactions can be carried out at different times and 
PGL-SV40 was used as internal control to normalize the results, being proportional to the 
efficiency of transfection. The expression plasmid pCR-50sp, encoding ORF50, a known 
transactivator of the promoters tested
56
 was used as a positive control. 
After transfection, cells incubated for 48 hours at 37° C were then collected for luciferase 
assay. In this experiment, 10
6
 cells samples were harvested and lysed following the 
manufacturer’s instructions (Dual Glo luciferase assay System) as described in Materials 
and Methods. Sample lysates were measured by luminometer. The signal emitted from the 
Firefly luciferase was measured after 20 minutes incubation at room temperature. 
Subsequently the Stop & Glo Reagent, containing the Renilla luciferase substrate was 
added and incubated for 10 minutes at room temperature, to perform the measurement of 
the Renilla luciferase emission necessary to standardize the results. 
 
 
62 
 
The results (Fig. 29) shows that ATF4 does not activate the promoter tested, and no 
synergic activity is observed in co-expression with ORF50. 
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C.  
 
Figure 29: Luciferase assays on Jurkat cells co-transfected with HHV-8 promoter report plasmids (pGL-
PR50, pGL-PR57, pGL-PRT1.1) and ORF50 or ATF4 or both. A: ATF4 activity on ORF50 promoter. B: 
ATF4 activity on ORF57 promoter. C: ATF4 activity on T1.1 promoter. 
 
 
5. ATF4 activates MCP-1 promoter 
Since the results demonstrated that ATF4 increases replication and transcription of HHV-8, 
but does not act on HHV-8 promoter and HHV-8 reactivation, we investigated whether 
ATF4 was involved in the activity of MCP-1. 
MCP-1 is a cytokine upregulated by HHV-8
41
 involved in angiogenesis. 
To study the activation of MCP-1 promoter, different constructs were used (provided by T. 
Yoshimura, National Cancer Institute, Frederick, MD)
57
. The MCP-1 promoter-luciferase 
constructs contain the proximal promoter of MCP-1 (pGLM-PRM), the proximal promoter 
and the distal enhancer (pGLM-ENH), and the promoter and the enhancer with mutations 
of the NF-kB sites (pGLM-MA1A2). 
Hela cells were seeded at optimal confluence and co-transfected with 1 μg total DNA 
consisting of: 400 ng of the MCP-1 promoters (pGLM-PRM, pGLM-ENH or pGLM-
MA1MA2), 400 ng pCG-ATF4 plasmid (or control vector pCR3.1-Uni), and 200 ng of 
pGL-SV40 reporter plasmid containing the Renilla luciferase. 
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After transfection, cells incubated for 48 hours at 37° C, were then collected for luciferase 
assay. Cells samples were harvested and lysed following the kit instructions (Dual Glo 
luciferase assay System) as described in Materials and Methods. Sample lysates were 
measured by luminometer. The signal emitted from the Firefly luciferase was measured 
after 10 minutes incubation at room temperature. Subsequently the Stop & Glo Reagent 
containing the substrate of Renilla luciferase was added and incubated 10 minutes at room 
temperature, to perform the measurement of the Renilla luciferase signal in order to 
standardize the results. 
ATF4 induces a 3,1-fold activation of the MCP-1 promoter in Hela cells, as shown in 
Figure 30, whereas no activation of the MCP-1 promoter with the enhancer and with the 
mutated enhancer is observed, suggesting that the NF-kB sites are not required for ATF4 
activity. 
 
 
 
Figure 30: Luciferase assay on Hela cells co-transfected with ATF4 and MCP-1 promoter report plasmid 
pGLM-PRM,  pGLM-ENH and pGLM-MA1MA2. 
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DISCUSSION 
 
 
HHV-8, also known as Kaposi’s sarcoma associated herpesvirus (KSHV), is a gamma-
herpesvirus initially identified by Chang et al. in 1994 from a Kaposi sarcoma biopsy
5
. 
HHV-8 is considered the primary etiologic agent of Kaposi sarcoma, a highly vascularised 
neoplasm characterised by the presence of spindle cells of endothelial origin, angiogenesis 
and inflammatory infiltrates. HHV-8 is also implicated in other malignancies like primary 
effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) and is associated 
with immunodeficiency and immunosuppression. The viral genome contains several genes 
homologous to oncogenes that induce malignant tumours. Development of HHV-8 
associated tumours is related to the replicative activity of the virus. In fact, a critical step in 
HHV-8 oncogenesis is represented by the activation of virus replication, mediated by the 
switch between latent and lytic phases. The major transactivator genes ORF50 and ORF57 
play an important role in the regulation of virus replication and reactivation. Both genes 
are expressed at early stages of infection.  
Previous results obtained in our laboratory by gene array on Jurkat cells stably expressing 
ORF50 gene showed that ORF50 upregulates the activating transcription factor ATF4 
(unpublished data). 
ATF4 is a signal-responsive member of the basic leucine zipper family of transcription 
factors. ATF4 is activated in response of several forms of cellular stress, such as hypoxia, 
amino acid deficiency and ER stress. ATF4 expression is upregulated in many tumours and 
is involved in angiogenesis by interaction with VEGF. Since angiogenesis is a key event in 
the development of Kaposi’s sarcoma induced by HHV-8 infection, we have focused our 
attention on this aspect, showing that HHV-8 induces a rapid and potent angiogenesis in 
cultured endothelial cells
41
. Induction of angiogenesis is due to the activation of MCP-1 
and NF-kB pathways. HHV-8 acute infection induces NF-kB activation in endothelial cells 
at levels comparable to those reached with the NF-kB inducer TPA. NF-kB controls the 
expression of several proinflammatory genes, and is a critical regulator of the immediate 
early response to HHV-8. MCP-1 is a cytokine NF-kB dependent and human MCP-1 gene 
contains two NF-kB binding sites in the enhancer region, required for TPA-induced 
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expression. Previous studies
41
 also demonstrated that HHV-8 infection selectively triggers 
the increase of MCP-1 levels. NF-kB is involved in this activation, and is required for 
maximal production of the cytokine. However, mutations in both NF-kB binding sites in 
the enhancer region did not result in the complete failure of promoter induction in HHV-8 
infected cells, moreover, inhibitors of NF-kB did not prevent MCP-1 activation, suggesting 
that other pathways are involved. 
Thus, due to the properties of ATF4, we explored the possibility of a role of this 
transcriptional factor in the angiogenesis induced by the virus. 
Firstly, to explain how HHV-8 and ATF4 interact, we investigated the effect of infection 
with HHV-8 on ATF4 expression in Jurkat cells, using a cell-free inoculum obtained in our 
laboratory, and we found that HHV-8 triggers the expression of ATF4 with a 10-fold 
increase 24 hours post infection. 
To further investigate whether the increase of ATF4 was functional to HHV-8 replication, 
we transfected Jurkat cells with the pCG-ATF4 plasmid and analysed the replication of the 
virus by real time PCR and rtPCR. The results showed a 15-fold increase of viral 
replication 24 hours post transfection, and a 10-fold augment of HHV-8 transcription. 
These data suggested an important role of ATF4 on HHV-8 replication, so we investigated 
whether ATF4 reactivated the virus from latency. In order to verify this hypothesis, we 
transfected PEL-derived cells BC-3 and BCBL-1, containing latent HHV-8, with the pCG-
ATF4 plasmid and analysed by real time PCR the viral replication. 
ATF4 did not induce reactivation of HHV-8 from latent state. To confirm this result, we 
analysed the effect of ATF4 on HHV-8 promoters. Three viral promoters were tested by 
luciferase assay: ORF50 promoter, ORF57 promoter and T1.1 promoter. ATF4 did not 
activate any of the promoter tested. 
Thus, to further understand how HHV-8 takes advantage from ATF4, we considered 
another important aspect of HHV-8 infection and ATF4 activity: angiogenesis. 
In order to investigate whether ATF4 was involved in the MCP-1 pathway of HHV-8 
infected cells, we studied the activation of MCP-1 promoter after overexpression of ATF4 
by luciferase assay. We analysed both MCP-1 promoter and MCP-1 promoter with 
mutation in the NF-kB binding sites and we found that ATF4 activates the enhancerless 
MCP-1 promoter. In addition, NF-kB binding sites are not required for this activation. 
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Therefore, we describe for the first time that ATF4 is a transcription factor important for 
HHV-8 replication. It is not yet possible to determine whether ATF4 is absolutely 
necessary or only an enhancing factor for virus replication, since ATF4 is constitutively 
expressed in the cell lines used in these experiments. Further experiments, performed by 
silencing ATF4, will elucidate this important novel aspect of HHV-8 replication. 
Furthermore, ATF4 might to be implicated in HHV-8 induced tumorigenesis, being 
involved in several aspects of viral replication, and could represent a potential therapeutic 
target for HHV-8 induced transformation. 
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REAL TIME PCR TO ASSESS TOTAL BACTERIAL LOAD 
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INTRODUCTION 
 
 
1. Microbial diversity in chronic wounds 
Chronic wounds are wounds that do not heal in a predictable amount of time the way most 
wounds do. Usually, wounds that do not heal within three months are considered chronic, 
and may never heal or may take years to do so. These wounds cause severe emotional and 
physical stress to patients, and are a major health care problem. In fact, non healing 
wounds lead to disability, decrease quality of life and are very expensive both on the health 
care system and on patients and their families. In the United States, the cost of chronic 
wounds exceeds 10 billion $ per year and constitutes over half of the total cost for all skin 
diseases
1,2
. There are also heavy indirect costs through loss of income, depression, impact 
on friends and family. 
The vast majority of chronic wounds can be classified into three categories: venous ulcers, 
diabetic and pressure ulcers. A small number of wounds that do not fall into these 
categories may be due to different causes such as exposure to radiations or ischemia. 
Venous ulcers, which usually occur in the legs, account for about 70% to 90% of chronic 
wounds and mostly affect the elderly. They are thought to be due to venous hypertension 
caused by improper function of venous valves, therefore prevent blood from flowing 
backward.  
Another major cause of chronic wounds is diabetes. Chronic wounds in diabetic patients 
are increasing in prevalence. Diabetics have a 15% higher risk for amputation than the 
general population due to chronic ulcer. Diabetes causes neuropathy, which inhibits 
nociception and the perception of pain. Thus, patients may not initially notice small 
wounds to legs and feet, and may therefore fail to prevent infection or repeated injury
3
. 
Further, diabetes damages small blood vessels, preventing adequate oxygenation of tissue, 
which can cause chronic wounds. Pressure also plays a role in the formation of diabetic 
ulcers.  
Another leading type of chronic wounds is pressure ulcer, which usually occurs in 
bedridden patients and in people with conditions such as paralysis, inhibiting movement of 
body parts that are commonly subjected to pressure such as heels, shoulder blades and 
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sacrum. Pressure ulcers are caused by ischemia that occurs when pressure in the tissue is 
greater than the pressure in capillaries, and thus restricts blood flow into the area. Muscle 
tissue, which needs more oxygen and nutrients than skin does, shows the worst effects 
from prolonged pressure. 
Chronic wounds affect mostly people over the age of 60. The incidence is 0,78% of the 
population and the prevalence ranges from 0,18 to 0,32%
4
. As the population ages, the 
number of chronic wounds is expected to rise
5
. 
Chronic wounds usually occur in patients with predisposing conditions, such as 
neuropathy, vascular compromission and venous disease, diabetes. In addition, other 
systemic conditions affect wound healing, such as trauma, inflammatory diseases, 
metabolic abnormalities, coagulopathies, etc. The main effect of these predisposing factors 
is the impairment of blood flow, resulting in local hypoxia and consequent decrease of 
leukocyte bactericidal action.  
Chronic wounds are colonized by polymicrobial flora, comprising commensal bacteria 
normally present in local skin flora and urogenital tract, but also obligate anaerobic 
bacteria, that can proliferate in the wound due to the combination of necrotic tissue and 
low oxygen tension. Some of the bacteria more frequently detected in chronic wounds are 
reported in Table 1. 
The role of bacteria in wound healing depends on their concentration, species composition 
and host response. Although bacterial colonization occurs in all chronic wounds, the 
differentiation between colonization and infection is not well defined. 
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AEROBES AND FACULTATIVE ANAEROBES ANAEROBES 
Coagulase-negative Staphylococci 
Staphylococcus aureus 
Peptostreptococcus spp. (P. magnus, P. 
micros, P. prevotii, P. indolicus, P. 
asaccharolyticus) 
Beta-hemolytic Streptococci 
Streptococcus spp. 
Clostridium perfrigens, C. difficile, C. baratii, 
C. cadaveris, C. ramosum, C. hystolyticum,  
C. sporogenes. 
Micrococcus spp. Eubacterium limosum 
Corynebacterium spp. 
C. xerosis 
Propionibacterium acnes 
Escherichia coli Bacteroides fragilis, B. ureolyticus, 
B. uniformis, B. stercoris, B. capillosus 
Serratia liquefaciens Prevotella oralis, P. oris, P. biviae, P. buccae,  
P. corporis, P. melaninogenica 
Klebsiella pneumoniae 
K. oxytoca 
Porphyromonas asaccharolytica 
Enterobacter cloacae 
E. aerogenes 
Gram-negative pigmented bacillus  
Citrobacter freundii Fusobacterium necrophorum 
Proteus mirabilis 
P. vulgaris 
Veillonella spp. 
Providencia stuarti  
Morganella morganii  
Acinetobacter calcoaceticus  
Pseudomonas aeruginosa  
Sphingobacterium multivorum  
 
Table 1: Bacteria frequently detected in chronic wounds. 
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The exposure of subcutaneous tissue to external environment provides a favourable setting 
for colonization by microorganisms. As previously mentioned, growth conditions become 
ideal when tissue is necrotic, or when the immune response is impaired. The most 
important sources of contamination are the external environment (for example bacteria in 
air, soil or on objects), the tissue surrounding the lesion (skin commensal flora) and 
endogenous sources, especially for lesions in proximity of body orifices (gastrointestinal 
tract, urogenital mucosa, oropharynx). Even if bacteria colonize the wounds and replicate, 
pathologic infection does not necessarily ensues. Infection takes place when virulence 
factors produced by colonizing bacteria prevail over local immune defences. An important 
contribution in promoting the passage from colonization to infection is represented by an 
elevate bacterial burden. 
The progression from colonized lesion to infected wound depends on several host and 
microbic factors, including characteristics of the lesion (extension, depth, site), host 
systemic conditions and immune status, microbial load, and synergies among different 
bacterial species. Further complications of the local ecology of chronic wounds are their 
metabolic characteristics, which can affect the genotype expression of the wound bacteria. 
Usually, chronic wounds show modifications of their bacterial flora over time. In the first 
phases, the wound is colonized by normal commensal flora from the skin, but in few weeks 
a significant increase of Gram-positive cocci take place. Subsequently, polymicrobial 
mixtures develop, comprising both aerobic and anaerobic bacteria. 
Many studies focused on the detection of bacteria by standard culture methods, but search 
for specific pathogens by qualitative microbiology has failed to differentiate colonizers 
from invading pathogenic microorganisms (reviewed by Martin et al, 2010)
6
. For example, 
chronic venous leg ulcer harbour staphylococci, enterococci and pseudomonas
7
. However, 
no pathogen is consistently detected in the majority of samples, and also comparisons 
among different studied is difficult, since they are based on different sampling methods, 
culturing procedures and often selecting specific bacterial groups. 
Furthermore, most studies investigated aerobic pathogens. However, also anaerobic 
bacteria are frequently present, even if fewer studies document their presence
8,9
, due the 
difficulties in isolating and identifying anaerobes in comparison to aerobes. 
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In fact, methods of specimen collections and transport to the laboratory are critical for 
viability of obligate anaerobes. Furthermore, the time required for their culture and 
isolation is prolonged and more resource demanding than investigation for aerobes. 
Until recently, the complexity of wound bacterial flora was underestimated, because 
standard culture techniques cannot identify all bacteria, particularly anaerobic bacteria that 
are difficult to isolate, and culture conditions might select bacterial species that are less 
represented in the in vivo lesion. Therefore, it has been difficult to establish the role of 
microorganisms in wound persistence, and to differentiate pathogenic bacteria that delay or 
prevent wound healing from innocent colonizers. Recently, several reports have 
strengthened the notion that the polymicrobic nature of infection, and the still 
undetermined interactions among colonizing bacteria, may play a major role in the absence 
of healing of chronic wounds
6,10
. 
Due to the impossibility of growing all bacteria, it is difficult to substantiate with precision 
a threshold of significance, but there is a growing perception that the presence of 10
5
 or 
more bacterial cells-per gram of tissue (determined by classic culture-based analysis) is a 
key determinant in delayed wound healing
11
. 
 
 
2. Rapid  molecular method for quantifying bacteria. 
Many different techniques have been applied to identify microorganisms in chronic 
wounds. Table 2 (published originally by Martin et al, 2010)
6
 summarizes the advantages 
and disadvantages of the most used methods. Traditionally, identification of wound 
bacteria has relied on standard bacteriological culture-based methods. These qualitative 
cultures are inexpensive, easy and quick to perform, however they completely miss the 
unculturable population that may be present. An important problem is given by the search 
of anaerobic bacteria, that frequently infect chronic wounds, but require specific culture 
conditions, suffer from transportation to the laboratory and can be refractory to in vitro 
growth. Furthermore, standard culture methods are insufficient for characterising complex 
polymicrobial communities, since many bacteria cannot be cultured. Moreover, bacteria 
that are present in only small quantities in most environments, including chronic wounds, 
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may proliferate readily in culture, whereas major populations, especially anaerobic ones, 
may require very specialised conditions to propagate under laboratory conditions.  
 
 
 
Table 2: Common methods used to analyze bacterial populations in chronic wounds (Martin et al, 2010)
6
. 
 
 
Quantitative cultural methods, aiming to define a threshold value of significance of 
bacterial burden, require at first the identification of bacteria, and subsequently 
quantification. This approach, in addition to the problems outlined above for standard 
bacteriological analysis, are labor intensive and clinical correlations are not well defined. 
Standard culturing methods depend on diagnostic growth conditions (nutrient, inhibitors, 
temperature, gases, pressure, etc.), and characterize only viable and culturable bacteria, 
while molecular methods, depending on diagnostic macromolecules (DNA), can 
characterize viable and non-viable, culturable and unculturable bacteria, fastidious or 
dormant. A widely used molecular method is polymerase chain reaction (PCR), a culture-
free molecular technique amplifying specific targets of DNA. However, PCR requires the 
use of oligonucleotide primers specific for a given bacterial species, and is not quantitative. 
Very recently, the use of metagenomic methods has been proposed. This approach requires 
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amplification of DNA and subsequent sequencing. Therefore, it is very labor-intensive, 
requires specialized laboratories, is expensive and time-consuming. 
Another method that is increasingly applied to bacterial determination in chronic wounds is 
real-time PCR, that allows precise quantification of bacterial load. This approach has been 
used to detect and quantify specific pathogens in chronic wounds
12,13
, but as outlined above 
for classic PCR, it requires the use of primers (and in this case also probes) specific for 
each bacterial species of interest. An important development of real-time PCR has been the 
design of “universal“ primers, focused on the 16S rRNA gene14. This is a region, 
conserved across a wide range of bacterial genome, that can be employed, and therefore 
allows to determine the total bacterial burden, with simultaneous quantification of bacterial 
DNA without distinguishing among different species. This approach, so far not yet applied 
to the study of chronic wounds, offers several advantages: 
 High sensitivity (about 100 fold more than classic culture methods) 
 Rapid results (the analysis can be performed in few hours) 
 Independent on the bacteria viability (transport methods are not relevant)  
 Detection of all bacteria present in the wounds, aerobic and anaerobic, easy to 
culturing and fastidious ones. 
The real time PCR used in this study amplifies the conserved region 16S ribosomal DNA. 
The 16S rRNA gene is highly conserved among the Domain Bacteria and different 
universal probes can be constructed to enumerate complex bacterial populations. 
The 16S rRNA is a part of the ribosomal RNA, component of the small prokaryotic 
ribosomal subunit 30S; it has a structural role, acting as a scaffold defining the positions of 
the ribosomal protein. It interacts with 23S to promote the binding of the two ribosomal 
subunits 50S and 30S. 
 
 
3. Cutimed Sorbact 
For many years chronic wounds have been treated with antibiotic therapies. Now it is 
known that antibiotic treatments have several disadvantages, such as selection for bacterial 
resistance, inability to penetrate in the wound because of the barrier created by the biofilms 
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formed by the microorganisms, toxicity and increase in the general costs and time of 
healing
15,16
. 
These limitations suggest the need to develop new treatments as a suitable alternative 
without the issue of the cost and bacterial resistance. 
Cutimed Sorbact, produced by BSN Medical GmbH (Hamburg, Germany), is an 
innovative dressing, coated with DACC (dialkyl-carbamoyl-chloride), a fatty acid 
derivative which makes the dressing highly hydrophobic. 
It is recognised that both aerobes and anaerobes are largely hydrophobic in nature and 
express cell-surface hydrophobicity. Once in physical contact with the wound bed, and in 
the presence of moisture, such as wound exudates, bacteria are hydrophobically attracted 
by DACC and bind to the dressing (Fig. 1), thus reducing the overall concentration of 
microbes in the wound. The binding starts 10 minutes after contact and reaches a 
maximum at 2 hours. Moreover, bacteria remain stably bound for several days, with a very 
low extent of replication.  
This unique mechanism of action means that Cutimed Sorbact is a useful dressing for 
reducing bacterial loads and can be an alternative to silver and other antimicrobials. 
There is no risk of bacterial resistance and no limitations of use in the patients. 
 
 
 
Figure 1: mechanism of action of Cutimed Sorbact. 
 
 
A hydrophobic dressing is a non-allergic, non-toxic alternative for reducing bacterial load 
in open wound without enhancing nosocomial spread and can reduce the use of antibiotics. 
Hydrophobic microorganisms bind to the dressing, preferably in a moist environment, and 
are removed with it. They multiply to quite a low extent when adsorbed in the dressing, 
and may not produce extracellular toxins and enzymes
17
. 
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AIM OF THE RESEARCH 
 
 
Chronic wounds usually occur in patients with predisposing conditions, such as 
neuropathy, vascular compromission and venous disease, diabetes. They are characterized 
by the fact that usually do not heal like normal wounds do and persist for long period of 
time. Chronic wounds are colonized by polymicrobial flora, comprising commensal 
bacteria normally present in local skin flora and urogenital tract, but also of obligate 
anaerobic bacteria, that can proliferate in the wound due to the combination of necrotic 
tissue and low oxygen tension. However, the role of bacteria in the pathogenesis of these 
lesions is still unclear. Even if all wounds are colonized by bacteria, it is practically 
impossible to differentiate between colonizing and invading microorganisms. Standard 
bacteriologic analysis is not always sensitive enough, and not all microorganisms grow in 
culture conditions. In fact, culturing techniques depend on diagnostic growth conditions, 
and although anaerobic bacteria often constitute a significant proportion of the total 
microflora in wounds, their culture is prolonged and more resource demanding. As a 
consequence, the need of new techniques to assess the total microbial load in wounds is 
increasing. Therefore, molecular approaches represent a promising alternative to the 
traditional time-consuming cultivation methods, and have been applied to the study of 
microbiology of chronic wounds. This work aimed to assess the usefulness of a pan-
bacterial quantitative real time PCR reaction to precisely quantitate the total bacterial load 
in chronic wounds treated with Cutimed Sorbact, a novel therapeutic approach based on 
hydrophobic binding of bacteria to a membrane, and to correlate the total bacterial burden 
with the clinical results obtained using this dressing. 
A highly conserved region of the bacterial gene 16S, present in all bacteria, was amplified 
with an universal set of primers and probe. The aim of the study was to verify whether 
determination of bacterial load could be an useful prognostic parameter to analyse biopsies 
and swabs derived from patients with chronic ulcers. 
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MATERIALS AND METHODS 
 
 
1. Clinical study 
A non comparative double-blind pilot study was carried out by the Vascular Disease 
Center (Ferrara, St. Anna Hospital), guided by Prof. P. Zamboni. Ethical approval was 
obtained from the Ethical Committee of the University of Ferrara by Prof. P. Zamboni. The 
aim of the pilot study was to assess the efficacy of a novel antibiotic-free treatment on 
chronic venous leg ulcers in a 4-week period. 
Nineteen patients (for a total of 20 wounds) affected by chronic venous leg ulcers were 
enrolled in the study and gave written informed consent. Specimens were transported to the 
laboratory under code to ensure patient’s privacy. 
Wounds were treated with Cudimed Sorbact (BSN Medical, Hamburg, Germany), an 
innovative non-antibiotic approach for chronic wound treatment. Cutimed Sorbact is a 
hydrophobic coated dressing that binds and removes microbes from the wound by 
hydrophobic interactions.  
The dressings were changed twice a week and the study was performed during a 4-week 
period. 
 
 
2. Wound sampling 
Punch biopsies were taken at the beginning and at the end of the treatment with Cutimed 
Sorbact, swabs were taken once a week during the dressing change. Tissue is obtained 
aseptically and is then put into a sterile tube containing 500 l of sterile phosphate buffered 
saline (PBS) and transported to the laboratory, where is weighted, homogenised and lysed. 
Wound swabbing involves the use of Cutimed dressing to sample superficial wound fluid 
and tissue debris. Dressings are put into a sterile tube containing 2 ml of sterile PBS and 
transported to the laboratory. 
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3. DNA extraction 
Biopsy and swab samples were respectively incubated in 2 ml and 3 ml lysis buffer (0,6% 
SDS, 10 mM Tris, 1 mM EDTA, 120 g/ml proteinase K) at 37°C overnight. 
Then, genomic DNA was extracted by four extractions with an equal volume of phenol: 
chloroform: isoamyl alcohol (25: 24: 1) mixture, using the Phase Lock Gel 15 ml tubes 
(Eppendorf). After isopropanol precipitation, DNA was centrifuged, washed with 75% 
ethanol and resuspended in 100 l of sterile water. DNA quantity was assessed by optical 
density reading at 260 nm using a spectrophotometer and by a second reading using the 
Qubit fluorometer (Invitrogen). Qubit fluorometer is a highly sensitive fluorescence-based 
quantitation system that uses fluorescent dyes selective for dsDNA, avoiding incorrect 
reading due to the presence of RNA or proteins. 
Purified DNAs were then stored at -20°C until real time PCR analysis. 
 
 
4. Bacterial strains 
Two bacterial strains used in this study were obtained from the American Type Culture 
Collection (ATCC, USA), including Bacteroides fragilis (ATCC 25285) and 
Fusobacterium necrophorum (ATCC 25286). Both strains were cultured in anaerobic 
condition for 48 or 72 hours at 37° C. The anaerobic conditions were created using the 
AnaeroGen sachet in the Anaerobic Jar (Oxoid), and assessed by the Anaerobic Indicator. 
Both bacteria were grown in CDC Anaerobe Agar with 5% sheep blood plates and in BBL 
cooked meat medium (Becton-Dickinson). 
  
 
5. Plasmid constructs 
Two plasmids were constructed to have standard curves of Bacteroides and 
Fusobacterium. The amplicons containing target regions for real time PCR analysis were 
produced using qualitative PCR of B. fragilis and F. necrophorum DNA, and amplified a 
specific region of the 16S rRNA gene. 
Primers sequences are shown in Table 3. 
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PRIMERS  SEQUENCES  AMPLICONS 
B.Frag-Forw 
B.Frag-Rev  
5'- GTCAGTTGCAGTCCAGTGAG -3‘ 
5'- GTAACACGTATCCAACCTGC -3'  
634 bps 
F.Necr-Forw 
F.Necr-Rev  
5'- GAGGTATGGAGACAGTGCTA-3‘ 
5'- GACAACTGGTACATCAGAGG -3'  
485 bps 
 
 
SPECIES 
 
SPECIES 
 
CONDITIONS 
 
CONDITIONS  
 
CYCLES 
 
CYCLES 
 
[MgCl2] 
 
[MgCl2] 
 
bacteroides 
94°C  5min  
94°C  30 sec, 63°C  1 min, 72°C  1 min + ext. 3 
sec/cycle  
72°C  10 min, 4°C >>>  
1 
35 
1 
 
2mM 
 
fusobacterium 
94°C  5min  
94°C  1min, 60°C  1 min, 72°C  1 min + ext. 3 
sec/cycle  
72°C  10 min, 4°C >>>  
1 
35 
1 
 
2mM 
 
Table 3: Primer sequences for ligations, and thermal conditions.  
 
 
PCR products were run on a 1,5% agarose gel to confirm the specificity of the 
amplifications. Both amplicons were then purified using the QIAquick PCR Purification 
Kit (Qiagen) and ligated into pCR2.1 vector (Invitrogen, Figure 2) using the TA-cloning 
kit (Invitrogen). After ligations, the transformation into TOP10F’ competent E. coli cells 
was performed following the manufacturer’s instructions. Blue/white screening of 
transformants was done on Luria-Bertani agar containing 50 mg/ml ampicillin and top–
spread with 20 mg/ml X-Gal solution.  
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Figure 2: Representation of the pCR2.1 map. 
 
 
Plasmid DNAs were extracted using the Zyppo Plasmid Miniprep Kit (Zymo Research), 
and EcoRI digestion to check the validity of cloning was performed. 
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6. Real time PCR 
Real time PCR or quantitative PCR (qPCR) was used to determine either the amount of 
total bacterial genomes with a panbacterial consensus set of primers and probe, and the 
amount of Bacteroides and Fusobacterium genomes with specific reactions.  
The reactions were performed using the 7300 Applied Biosystems PCR equipment. 
 Eubacterial qPCR: 
The DNA copy numbers were quantified by comparison with a 10 fold serial 
dilutions of known concentration of E. coli (ATCC 10536) genomic DNA. The 
concentration of the standard DNA was assessed by spectrophotometer and genome 
copy number was calculated to prepare standard curve (10
7
 to 10 copies). 
Efficiency of the reaction was similarly assessed using standard curves obtained 
with S. aureus (ATCC 25923), P. aeruginosa (ATCC 15442), E. hirae (ATCC 
541), S. agalactiae (ATCC 12344) and B. subtilis (ATCC 6633) bacterial genomes. 
The 16S rRNA gene was amplified using TaqMan 5’-FAM-labelled and 3’-
TAMRA-labelled probe. The RNAseP eukaryotic gene was amplified using a 5’-
VIC-labelled and 3’-non fluorescent (MGB, Applied Biosystems) probe. Primers 
and probes for panbacterial qPCR were those described by Yang et al, 2002
18
, 
except for modification of the reporter dye. 
 Bacteroides and Fusobacterium qPCR: 
Primer and probe sets for qPCR were designed on the sequence of standard PCR 
amplification products. The DNA copy numbers were quantified by comparison 
with a 10 fold serially diluted pCR-bact and pCR-fuso plasmids. The concentration 
of the standard plasmids was assessed by spectrophotometer and plasmid copy 
number was calculated to prepare standard curves (10
7
 to 10 copies). The targets 
were amplified using TaqMan 5’-FAM-labelled and 3’-TAMRA-labelled probe. 
The RNAseP eukaryotic gene was amplified using a 5’-VIC-labelled and 3’-non 
fluorescent (MGB, Applied Biosystems) probe. 
 
RNAseP gene was simultaneously quantified to calculate the number of eukaryotic cells 
present in the samples, as an internal positive control to ensure that all samples were 
suitable for amplification. 
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Amplifications were carried out in a 50 l total volume containing 25 l 2X TaqMan 
Universal Master Mix (Applied Biosystems), 2,5 l of primers and probes mix, 2,5 l of 
20X RNAseP mix and 20 l template corresponding to 100 ng total DNA. 
Sequences of primers and probes used are shown in Table 4. Concentrations were 900 nM 
of each primer, 100 nM each probe and 1X RNAseP. 
The reaction condition for all template were: 10 minutes at 95°C for enzyme activation, 10 
cycles with 15 seconds at 95°C for DNA denaturation and 60 seconds at 60°C for 
annealing and extension. Fluorescence data were collected in the primers elongation step at 
60°C. 
All samples were amplified in duplicate, and the average value was calculated. 
 
 
GENES 
PRIMERS & 
PROBES 
 
SEQUENCES  
 
16S rRNA* 
UNI-Forward 
UNI-Reverse 
UNI-Probe 
5'-TGGAGCATGTGGTTTAATTCGA -3‘ 
5'-TGCGGGACTTAACCCAACA -3'    
5’-(6Fam) CACGAGCTGACGACARCCATGCA (Tamra)-3’ 
 
Fusbacterium 
23S rRNA 
Fn-Q-Forward 
Fn-Q-Reverse 
Fnecr-Probe 
5’- CCGCGCATTCCGTATGG-3’ 
5’- CGGGTAGGATCAGCCTGTTATC -3’ 
5’-(6Fam) TCGTCGCTCAACGGATAAAAGCTACCCT (Tamra)-3’ 
 
Bacteroides 
BFr-Q-Forward 
BFr-Q-Reverse 
BFrag-Probe 
5'- TTCAGGCTAGCGCCCATT -3'  
5'- GGAACTGAGACACGGTCCAAAC-3'  
5’-(6Fam) CCAATATTCCTCACTGCTGCCTCCCGTA (Tamra)-3’  
RNAseP** Endogenous reference for 
multiplex reactions Pre-designed primers and VIC-labelled probe mix 
 
Table 4: Oligonucleotide sequences of primers and probes used in the study. 
 * primer and probe set was taken from literature and used in our laboratory after modification of the 
reporter dye. (Yang et al, 2002)
18
. 
** RNAseP mix is optimized by Applied Biosystems. 
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7. Isolation of Staphylococcus and Pseudomonas spp by culture methods 
Classic cultures were performed by Prof. P.G. Balboni (University of Ferrara). 
Briefly, 1/10 volume of biopsies and swabs were plated in selective agar for the growth of 
Staphylococcus and Pseudomonas species. Detection of staphylococci was performed on 
Mannitol Salt agar plates (Oxoid), and Pseudomonas spp were selected on Cetrimide agar 
plates (Oxoid). After 24 and 48 (respectively) hours incubation at 37°C, the number of 
colony forming units (CFU) of each microorganism was counted for each plate. 
 
 
8. Statistical analysis 
Statistical analysis was performed by non-parametrical Mann-Whitney test, used for 
assessing whether two independent samples of observations come from the same 
population. 
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RESULTS 
 
 
1. Sensitivity of eubacterial real time PCR 
To assess the sensitivity of qPCR, the primers and probe for eubacterial detection were 
checked on standard curves obtained with different bacterial DNAs. 
DNA was extracted as described in Material and Methods from: 
 E. coli (gram negative) 
 S. aureus (gram positive) 
 P. aeruginosa (gram negative) 
 E. hirae (gram positive) 
 S. agalactiae (gram positive) 
 B. subtilis (gram positive) 
As negative controls, DNA extract from C. albicans (mycete, ATCC 10231) and from 
Jurkat cells (eukaryote) were used.  
To assess the sensitivity of the broad range real time PCR, serial dilutions from 10
7
 to 100 
molecules of bacterial DNA were used in the reactions.  
Fig. 3 shows the results of two representative standard curves obtained from purified DNA 
of E. coli and B. subtilis. All 6 bacterial species at each concentration tested were correctly 
amplified and detected (data not shown). The linear range of amplification was consistent 
regardless of the number of target molecules present in the amplification reaction. 
DNA extracted from bacterial cultures was carefully quantified by spectrophotometric 
analysis and by Qubit fluorometer (Invitrogen). 
Quantification was reliable starting from 100 up to 10
7
 target DNA molecules. All different 
bacterial DNAs were amplified with the same efficiency. Negative controls failed to be 
amplified by qPCR, being detected over the 39
th
 amplification cycle (Ct, threshold of 
detectability). 
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Figure 3: Representative standard curves obtained from purified DNA of B.subtilis and E.coli. The slopes (-
3,19 and -3,33 respectively) obtained are in the linearity range required for correct quantification.  
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2. Clinical results 
Clinical data were assessed by the medical team of Prof. P. Zamboni (Vascular Disease 
Center, University of Ferrara). In particular, the area affected by chronic lesion was 
measured at the time of first biopsy, and once a week, until the end of the study period, and 
the data were transferred to our laboratory under code, to protect the patient’s privacy.  
Treatment with Cutimed Sorbact resulted in a significant clinical outcome in 75% of 
wounds, defining a positive outcome when the affected area was reduced by 20% or more.  
 
 
3. Total bacterial load in chronic wounds. 
The total load of the bacterial DNA was quantified from biopsies and swabs of 20 chronic 
wounds. Swabs from 6 healthy skins were used as controls. 
Quantification of total bacterial load was assessed by comparison to the standard curve 
obtained by 10-fold serially diluted purified DNA of E. coli. 
In the case of biopsies, all reactions were performed on 100 ng of total DNA, 
simultaneously amplifying the highly conserved bacterial 16S rRNA gene and the 
eukaryotic RNAseP gene, used as internal control to assess that all the samples were 
suitable for amplification. 
In the case of swabs, reactions were performed on 100 ng of total extracted DNA 
amplifying the bacterial 16S rRNA gene, and then the results were normalized to the total 
volume of extraction buffer where swabs were initially soaked. 
The mean of the bacterial load in normal healthy skin was 4,5^10
5
 bacteria per swab, that 
represent the normal flora colonising our skin. 
Figure 4 shows the total bacterial load of swabs and biopsies and the difference of the 
wound’s area (clinical data) for each patient (enumerated 1 to 20) during 4 weeks of 
treatment with Cutimed Sorbact.  
 
 
 
 
 
 
95 
 
 
 
 
 
96 
 
 
 
 
 
 
 
97 
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Figure 4: Summary of the results obtained for each patient. Numbers 1-20 represent patients. The first 
column of plots shows the total bacterial load of the first and the last biopsy; bacterial load is expresses by 
number of genomes detected per mg of tissue. The second column of plots shows the total bacterial load of 
the four swabs collected during the four weeks of treatment. The third column of plots represents the area of 
the wound (%) at the time of first and last biopsy, where the first measurement is assumed as 100%. 
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We evaluated the correlation between the molecular data obtained by real time PCR and 
the clinical data, in particular considering the area of the wound. The results allowed to 
divide the samples into 3 groups. 
1. Clinical positive results concordant with molecular data: 
The first group is constituted by samples where the positive clinical outcome is 
concordant with molecular data. In particular, 10/15 wounds (66%) with a positive 
clinical outcome, with 58% mean reduction of the wound’s area, showed a significant 
decreases of the total bacterial load. The initial bacterial load was considerably 
different in the samples, ranging from 4,38^10
3
 to 2,44^10
8
 bacterial genomes/mg of 
tissue. Nevertheless, the average of the total bacterial load at the beginning of treatment 
was 4,41^10
7
/mg of tissue, and at the end decreased to 1,73^10
5
/mg of tissue, 
corresponding to a 254-fold decrease of the total bacterial load (Fig. 5). The decrease 
of bacterial load was statistically significant (p=0,0243). 
 
 
  
Figure 5: Total bacterial load of biopsies with concordant clinical and molecular results; p=0,0243. 
Bars represent standard errors. 
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Swabs of the same wounds were also considered. Swabs were collected once a week for 
4 weeks. 100 ng of DNA extracted from swabs was amplified by real time PCR. In this 
case there was less variability among samples from different patients, and the majority 
of specimens yielded over 10
6
 total bacteria in the first point. Analysis of the bacterial 
load in the course of clinical study failed to show any significant decrease. In fact, in 
spite of clinical positive outcome, the bacterial load remained constant, ranging from 
2,63^10
10
 in the first samples to 9,37^10
9
 bacterial genomes/swab in the final samples 
(Fig. 6).  
 
 
 
Figure 6: Total bacterial load of swabs representing the positive outcome of wounds (correlation 
between molecular and clinical data). 
 
 
2. Clinical negative results concordant with molecular data 
The second group is constituted by five chronic wounds that showed a negative 
clinical course, with no response to treatment, and averaged a 27% increase of the 
area. 
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The total bacterial load of biopsies of these five wounds showed a non-significant 5,2-
fold decrease at the end of the treatment (2,73^10
6
 to 5,22^10
5 
bacterial genomes / mg 
of tissue; p=0,6)(Fig. 7). 
 
 
 
Figure 7: Total bacterial load in biopsies that did not have a positive clinical result (correlation 
between molecular and clinical data); p=0,6. 
 
 
The swabs from these five wounds did not show any significant change in bacterial 
load, ranging from 6,50^10
9 
to 1,71^10
10
 bacterial genomes/swab along the 4-weeks 
period of the study (Fig. 8). 
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Figure 8: Total bacterial load of swabs representative for the negative outcome of wounds 
(correlation between molecular and clinical data). 
 
 
3. Clinical positive results not correlating with molecular data 
The last group of samples is represented by 5 chronic wounds that had a positive 
clinical outcome, with an average 50% decrease of the affected area, but there was no 
reduction of total bacterial load in biopsies. In fact, a slight, non significant 5,3-fold 
reduction was recorded (p=0,75)(Fig. 9). 
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Figure 9: Total bacterial load in biopsies with discordant results between molecular and clinical data 
(positive clinical outcome and no reduction of bacterial load); p=0,75.   
 
 
Similarly, the total bacterial load in swabs remained unchanged until the end of the 
treatment, at high levels of about 10
10
 bacterial genomes per swab (Fig. 10). 
 
 
 
Figure 10: Total bacterial load in swabs representing the discordant results between molecular and 
clinical data.   
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4. Real time PCR sensitivity of anaerobic bacteria. 
To quantify the bacterial load of two anaerobes frequently detected in chronic wounds, we 
used primers and probes specific for Fusobacterium and Bacteroides species. To test the 
sensitivity of reaction, and to build the standard curve, genomic DNA and pCR2.1 
plasmids containing the amplified region of Fusobacterium and Bacteroides were serially 
diluted, and both reactions were sensitive enough to detect as few as 100 total genomes. 
No cross-reaction between primer and probe sets was observed, and no amplification of 
eukaryotic cell DNA and other bacterial DNA was present using these sets of primers. As 
shown in Figs 11 and 12, the linear range of amplification was achieved from 10
3
 to 10
7
 
total molecules. 
 
 
Figure 11: Representative standard curve of the real time PCR for the detection of F. necrophorum. 10-fold 
serially diluted DNA was obtained with the pCR-Fuso plasmid. 
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Figure 12: Representative standard curve of the real time PCR for the detection of B. fragilis. 10-fold 
serially diluted DNA was obtained with the pCR-Bact plasmid. 
 
 
5. Quantification of anaerobes in chronic wounds. 
 Bacteroides spp: 
Bacteroides genomes were quantified in DNA extracted from biopsies. 
The amount of DNA used was the same utilised in the eubacterial qPCR reactions (100 
ng). Simultaneously, RNAseP gene was quantify to calculate the number of eukaryotic 
cells present in each specimen (internal control). 
Bacteroides genomes were found in 10/20 (50%) of the wounds. The anaerobe’s load 
showed a 197–fold decrease after treatment with Cutimed Sorbact, indicating that the 
dressing is also able to bind the anaerobic bacteria, but there was no statistical 
difference between the first and last biopsy (p=0,1)(Fig. 13). 
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More specifically, Bacteroides DNA was present in 6 wounds belonging to the first 
group of samples (positive correlation between total bacterial load and clinical 
outcome), in 3 wounds of the second group (absence of positive clinical result) and in 
one wound of the third group of samples (positive clinical result with no decrease in 
total bacterial load). 
 
 
 
Figure 13: Bacteroides genome number present in 10/20 biopsies (p=0,1). 
 
 
 Fusobacterium spp: 
Fusobacterium genomes were quantified by qPCR in biopsies. 
The amount of DNA used was the same utilised in the eubacterial qPCR reactions (100 
ng). Simultaneously, RNAseP gene was quantified to calculate the number of 
eukaryotic cells present in specimens. 
Fusobacterium species genomes were found in 10% of the wounds (2 patients), and  
the load showed a non significant 3,5–fold decrease after treatment with Cutimed 
Sorbact. The Fusobacterium genome number ranged from 1,7^10
4
 to 4,9^10
3
 
genomes/mg of tissue (Fig. 14). 
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Figure 14: Fusobacterium genome number present in 2/20 biopsies. 
 
 
6. Classic microbiologic culture results 
Biopsies were also analysed by classical culture methods by plating on selective agar for 
the detection of Staphylococcus spp and Pseudomonas spp. The colony count in the normal 
healthy skin was under 100 CFU, thus, in wounds, we considered positive values over 100 
CFU. 
The results are summarized in Table 5, where the data obtained by culture are shown with 
the clinical and molecular data. 
The results show that data from culture methods do not correlate with results from qPCR 
or with clinical ones. 
For example, patient 1 had a complete clinical recovery, with a marked decrease of 
bacterial load by qPCR, in complete absence of Staphylococcus and Pseudomonas spp in 
both biopsies. By contrast, patient 2 had a significant clinical outcome and a corresponding 
decrease of bacterial load, with the presence of Staphylococcus and Pseudomonas spp both 
in the first and in the last biopsy. 
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STAPHYLOCOCCUS PSEUDOMONAS 
PATIENTS AREA 
(%) 
BACTERIAL LOAD 
(N°FOLD) 
FIRST 
BIOPSY 
LAST 
BIOPSY 
FIRST 
BIOPSY 
LAST 
BIOPSY 
1 -100 -158000 - - - - 
2 -50 -4535 + + + + 
3 -100 -4380 - - - - 
4 -90 -313 - - - - 
5 -71,4 -120 + - - - 
6 -40 -58,2 + - - - 
7 -42,6 -11,7 + - - - 
8 -34,6 -12,6 - - - - 
9 -21,3 -8,2 - - - + 
10 -46,3 -6,1 + + - - 
11 +5,8 +56 + + - - 
12 +72,7 +1,2 - - - - 
13 +58,3 +1,7 + + - - 
14 -0,5 -42,7 - - + - 
15 +1,1 -1,4 - - - - 
16 -44,7 +22,4 + + + + 
17 -64,3 -1,8 + - - - 
18 -33,3 +1,1 + - - - 
19 -43,8 +1,3 + + - - 
20 -66,7 +5,1 - + - - 
 
Table 5: Grouping of clinical, molecular and microbiologic results. Area is expressed as percentage 
difference and bacterial load as fold difference. Staphylococcus and Pseudomonas spp are represented as 
positive where CFU exceed 100 units, and negative where CFU are below 100 units. 
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DISCUSSION 
 
 
The impact of microorganisms on chronic wounds has been extensively studied using 
different approaches, aiming especially to elucidate their possible role in the lack of 
healing (reviewed by Howell-Jones et al, 2005)
19
. Often, it is difficult to compare studies, 
because of different methods of specimen collection and, especially, different methods of 
bacteriological analysis. A further complication is represented by the nature of infected 
chronic wounds, which present a polymicrobial population, with a complex ecology
20
. 
Studies performed by standard bacteriological techniques have shown that the mean 
number of bacterial species per wound ranges from 1.6 to 5.4
10,19
, and that also wounds 
with no clinical sign of infection contain more than one bacterial species
21
. Therefore, even 
if several studies have described some bacteria as being the prevalent microorganism in 
chronic wounds, such as Staphylococcus aureus
22
, Pseudomonas aeruginosa
23
, and 
Bacteroides spp
24
, their association with infection (vs colonization) and lack of healing is 
far from being established.  
Until recently, the bacteria associated with chronic wounds have been analysed by 
standard, culture-dependent bacteriological methods, by taking a swab or biopsy from the 
wound and using it to inoculate different growth media. The development of molecular 
methods has demonstrated that culture-dependent methods underestimate the presence of 
bacteria, especially in the case of ulcers with slow-growing, fastidious or anaerobic 
microbes
25,26,27
. In particular, Davies et al (2004)
20
 reported that 40% of microorganisms 
identified in chronic wounds by molecular methods could not be cultured by classical 
methods, even if most of them were species that are usually considered to grow well on 
agar plates. In a recent study, it was described that molecular methods detected anaerobic 
pathogen that had not been detected with anaerobic cultures
10
. The same study described 
that culture experiments showed the presence of 12 different species in chronic wounds 
compared with the 33 species found with molecular methods
10
. 
 Molecular techniques applied to the study of microbiology of chronic wounds 
comprise (reviewed by Martin et al, 2010)
6
: 
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 normal PCR, which uses organism-specific primers and therefore different 
reactions are needed to detect each pathogen  
 real time PCR, applied to selected pathogens, which also requires organism-specific 
primers but has the advantage of giving a precise quantitation of the specific pathogen 
 metagenomic methods, either by large scale genomic pyrosequencing, or by 
denaturant gradient gel electrophoresis (DGGE) fingerprinting. 
It is relevant to note that so far qPCR to evaluate the total bacterial load has not been 
applied to the study of chronic wounds. 
While the main treatment of chronic wounds aims to address the underlying causes, often 
both compression bandages (to relieve edema) and antibiotics are prescribed to these 
patients. However, O’Meara et al (2000)28 analysed existing studies on the use of 
antibiotics in chronic wounds and drew the conclusion that there is insufficient evidence 
for their use in wound healing. Furthermore, a more updated search of the literature found 
that conclusive studies regarding the use of systemic antibiotics have not been published in 
more recent years
19
. The need for treatment is strong, and the lack of established, proof-
grounded guidelines has led to develop less conventional methods, such as debridement by 
using larvae from the fly Lucilia sericata to remove necrotic tissue and bacteria from the 
wound, thus aiding the healing process
29
. An innovative treatment is represented by 
Cutimed Sorbact, a membrane with hydrophobic properties allowing binding and retention 
of bacteria, enhancing the natural healing process. This approach has the advantage of 
having no unpleasant collateral effect and the inability of bacteria to develop resistance, 
invariably associated to the use of antibiotics. 
This work aimed to verify the suitability of qPCR quantification of total bacterial load as a 
quick and sensitive laboratory parameter in the course of a clinical study on the use of 
Cutimed Sorbact  for healing of chronic wounds. To achieve the goal, a panbacterial qPCR 
based on amplification of a conserved region of the 16S gene was set up, and verified on 
the genome of six different bacteria. The results (Fig. 3) show that this approach was 
sensitive and allows precise quantification over a broad range of concentrations (from 100 
to 10
7
 target molecules).  
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The clinical results show the success of the therapy in 15/20 patients. The laboratory 
results on panbacterial qPCR and identification of specific pathogens can be summarized 
as follows: 
 Total bacterial load significantly decreased in 10/15 healing chronic wounds 
 Total bacterial load did not change in 5/5 non healing chronic wounds 
 Decrease of bacterial load was shown in biopsies, but not in swabs 
 Classical microbiology for two aerobes widely predominant in chronic wounds (S. 
aureus, P. aeruginosa) did not show any correlation with the clinical outcome of the 
therapy 
 Molecular quantification for two anaerobes often implicated in chronic wounds 
(Bacteroides, Fusobacterium) did not show any correlation with the clinical outcome. 
Several interesting and original observations arise from this study. 
The first result is that panbacterial qPCR can be a reliable method to assess the therapeutic 
success of chronic wound treatment. In fact, 10/15 chronic wounds with therapeutical 
success showed a significant decrease of total bacterial load, and no decrease was observed 
in 5/5 wounds with no clinical improvement. In total, the results of qPCR were concordant 
with clinical data in 15/20 chronic wounds, indicating that might be considered as an 
useful biomarker for treatment prognosis. This is an important observation. In fact, the 
scientific literature highlights the need of prognostic indicators for chronic ulcers. A recent 
review enumerates several potential biomarkers (cytokines, proteases and their inhibitors, 
senescence markers, oxidative stress, microbiological status, etc.) but concludes that no 
available data reflect wound progression or regression
30
. Our study indicates that 
panbacterial qPCR might fill this need. 
Another observation is that quantification studies of chronic wounds by panbacterial real-
time PCR require analysis of biopsies. In fact, no significant result was obtained by 
analysis of swabs (Figures 6, 8, 10). Even if this result cannot be explained at the moment, 
it is possible that chronic wounds, even at an advanced stage of healing, are still colonized 
by a high number of bacteria at the surface, while infection of deep tissues has been 
eliminated. According to this hypothesis, bacterial swabs would just indicate the presence 
of colonizing bacteria while infectious processes are being eliminated. 
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Furthermore, the analysis for specific pathogens is much less sensitive than panbacterial 
qPCR, and could even be misleading. In fact, by conventional culture S. aureus and P. 
aeruginosa were not detected in sample n° 12 (Table 5), and yet this lesion was refractory 
to treatment and showed a substantial increase of wound area. Furthermore, both bacteria 
continued to be present in sample n° 2, even if this lesion responded well to therapy with a 
significant decrease of affected area. A similar situation was observed by analysis of 
anaerobes by real-time PCR. No significant decrease of Bacteroides was recorded in 
healing wounds, and this anaerobic bacteria had similar loads in healing and non healing 
lesions (Fig. 13). 
At the moment it is not possible to explain with convincing arguments the fact that 5 
chronic wounds showed a positive clinical outcome with no decrease of total bacterial 
burden. One plausible explanation is that the bacterial population in these wounds was only 
a minor pathogenic component, or that the presence of bacteria reflected colonising, but 
not infecting, microorganisms. Alternatively, it is possible that there was a switch in the 
composition of the bacterial population, and that more aggressive bacteria present in the 
first biopsy had been replaced in the last biopsy by commensal microorganisms. However, 
it should be noted that S. aureus, P aeruginosa and Bacteroides were not involved in this 
hypothetical process. 
In conclusion, these results show that panbacterial qPCR is a promising fast method for 
determining the total bacterial load in chronic wounds, and suggest that it might be an 
important biomarker for the prognosis of chronic wounds under treatment. 
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